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Abstract 
Drug carrier plays a critical role in achieving therapeutic effect in human or animals. Existing commercial 
drug carriers are mostly chemically synthesized, making the materials polydisperse in size, carry heavy 
residuals and extremely difficult to functionalize for bioactivity. Recombinant protein expressed through 
molecular biology presents a promising alternative to chemically synthesized materials due to several 
advantages. Molecular biology techniques allow for precise design of the genetic sequence, thus giving 
the recombinant protein the ability to incorporate specific motifs that mediates cell recognition. Protein 
expressed through molecular biology would have the exact amino acid sequence as designed and 
monodisperse in weight, which makes recombinant protein superior than synthesized materials for 
quality control purposes. For this thesis, we have chosen a naturally occurring plant protein oleosin, which 
has been previously demonstrated in our lab to self-assemble into a variety of nanostructures upon gene 
modification, as the starting template. We have designed many variants of oleosin to self-assemble into 
spherical micelles and carry bioactive motifs. First, we created a variant of oleosin that possesses dual 
control by protecting the bioactive ligand RGDS with a thrombin cleavable domain. Cellular uptake studies 
showed that this model is effective in protecting 74% of the RGDS bioactivity in 15 hours when interacted 
with breast cancer cells. We further enhanced the cellular uptake performance of oleosin by inserting a 
synergy PHSRN and cell penetrating peptide HIV-1 Tat, where the Tat peptide and the RGDS motif 
combination increased cell uptake by sixfold in 15 hours. We proved the ability of oleosin micelles to carry 
a cargo by successfully encapsulating an anti-cancer drug paclitaxel into oleosin micelles through brief 
sonication, and achieved integrin mediated cell killing on breast cancer cells over 15 hours. We then 
applied our oleosin variants to other cell lines by functionalizing with AFA and BPT ligands, and observed 
significantly improved cell killing on non-small cell lung cancer cells. All protein variants were confirmed 
for molecular weight and purity by gel electrophoresis and mass spectroscopy, and the second structures 
analyzed through circular dichroism. Protein self-assembly sizes were analyzed by dynamic light 
scattering. Oleosin micelles were stable in aqueous solutions for at least one month under refrigerated 
conditions, and has been found to be stable after drug encapsulation and variant blending. Oleosin has 
been shown to be a versatile and powerful tool for drug applications, and these results opened a new 
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Daniel A. Hammer 
 
Drug carrier plays a critical role in achieving therapeutic effect in human or animals. 
Existing commercial drug carriers are mostly chemically synthesized, making the 
materials polydisperse in size, carry heavy residuals and extremely difficult to 
functionalize for bioactivity. Recombinant protein expressed through molecular biology 
presents a promising alternative to chemically synthesized materials due to several 
advantages. Molecular biology techniques allow for precise design of the genetic 
sequence, thus giving the recombinant protein the ability to incorporate specific motifs 
that mediates cell recognition. Protein expressed through molecular biology would have 
the exact amino acid sequence as designed and monodisperse in weight, which makes 
recombinant protein superior than synthesized materials for quality control purposes. For 
this thesis, we have chosen a naturally occurring plant protein oleosin, which has been 
previously demonstrated in our lab to self-assemble into a variety of nanostructures upon 
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gene modification, as the starting template. We have designed many variants of oleosin to 
self-assemble into spherical micelles and carry bioactive motifs. First, we created a 
variant of oleosin that possesses dual control by protecting the bioactive ligand RGDS 
with a thrombin cleavable domain. Cellular uptake studies showed that this model is 
effective in protecting 74% of the RGDS bioactivity in 15 hours when interacted with 
breast cancer cells. We further enhanced the cellular uptake performance of oleosin by 
inserting a synergy PHSRN and cell penetrating peptide HIV-1 Tat, where the Tat 
peptide and the RGDS motif combination increased cell uptake by sixfold in 15 hours. 
We proved the ability of oleosin micelles to carry a cargo by successfully encapsulating 
an anti-cancer drug paclitaxel into oleosin micelles through brief sonication, and achieved 
integrin mediated cell killing on breast cancer cells over 15 hours. We then applied our 
oleosin variants to other cell lines by functionalizing with AFA and BPT ligands, and 
observed significantly improved cell killing on non-small cell lung cancer cells. All 
protein variants were confirmed for molecular weight and purity by gel electrophoresis 
and mass spectroscopy, and the second structures analyzed through circular dichroism. 
Protein self-assembly sizes were analyzed by dynamic light scattering. Oleosin micelles 
were stable in aqueous solutions for at least one month under refrigerated conditions, and 
has been found to be stable after drug encapsulation and variant blending. Oleosin has 
been shown to be a versatile and powerful tool for drug applications, and these results 
opened a new horizon for oleosin to be further engineered and utilized for therapeutic 
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1.1 An Overview of Drug Delivery 
 
 
Cancer remains to be one of the leading causes of death in the world. Over the past few 
decades, significant advances in fundamental cancer biology have led to better diagnostic 
tools and treatment methods. Despite these changes, mortality of cancer remains high. In 
2016, there is an estimated 1,685,210 diagnoses and 595,690 deaths from cancer in the 
United States alone.1 Current therapeutics for most cancers involve surgical resection, 
radiation therapy, and chemotherapy. These treatments are associated with significant 
mortality due to their non-specific effects on surrounding tissues. The efficacy of a 
therapeutic can be greatly improved if the carrier can selectively target diseased tissue, 
respond to the disease environment, and overcome biological barriers.2 Nanotechnology 
coupled with effective therapeutic agents is a promising strategy to address these 




The basic properties required for drug and imaging agent carriers are that they are 
biodegradable, biocompatible, and able to carry both hydrophilic and hydrophobic 
cargos.4–6 Nano-scale carriers can be of different constructs, each with their strengths and 
weaknesses. Vesicles are hollow spherical structures with an aqueous interior and the 
shell composed of amphiphilic molecules, and presents as promising carriers due to their 
ability to carry a large payload of aqueous drug, and their ability to also carry 
hydrophobic drugs.7 However, lipid vesicles have some drawbacks, including poor 
colloidal stability, short shelf life, restricted and expensive conditions of 
preparation/fabrication complexity, and they only work best for works well for soluble 
drugs.8 On the other hand, spherical micelles are formed by amphiphilic materials in 
aqueous solutions where the hydrophobic blocks come together to form the hydrophobic 
core, protected by the solvated hydrophilic corona. The hydrophobic block region can 
serve as a reservoir for poorly soluble drugs. Micelles are of particular interest due to 
their small size, biocompatibility, and are ideal candidates for applications such as 
intravenous administration or for crossing the blood-brain barrier.9–12 Micelles of 
elongated morphology, often referred to as wormlike micelles or filomicelles, have 
shown to have double the drug loading capacity, sustainably shrink tumors, as well as 
prolonged circulation times, when compared to spherical micelles of the same 
composition.13–16 
 
 Over the past few decades, there has been increasing interest in constructing 
delivery nanomaterials that are robust, stable, and can be engineered to both incorporate 
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targeting moieties and promote sustained release. Targeting, in particular, has the 
potential to reduce harmful systemic side effects such as systemic toxicity; the challenge 
is to find suitable materials that are both robust and can be easily functionalized.   
 
Phospholipid molecules are extensively studied for their potential to construct 
delivery vesicles.17,18 Phospholipid and lipid blends readily form biocompatible vesicles. 
However, phospholipid vesicles have limited potential due to their lack of mechanical 
and chemical stability. Phospholipid vesicles are mechanically weak and does not survive 
against the shear stress in blood circulation.19 Chemically, phospholipids oxidize quickly 
and are hard to modify to incorporate bioactive sites. In order to improve upon the 
deficiencies of phospholipid vesicles, studies have been done on numerous synthetic 
materials to construct vesicles that are both physically and chemically stable. Materials 
such as block copolymers and amphiphilic dendrimers can be made with a variety of 
different chemistries and molecular weights to achieve widely tunable mechanical 
properties.20–22 Polymersomes and dendrimersomes can be covalently linked to ligands 
for targeting. However, the addition of ligands on the vesicle surfaces can lead to changes 
in the phase behavior of polymers and dendrimers, and can even perturb the assembled 
structure away from the vesicular phase.23 Furthermore, synthetic materials, such as 
polymers, cannot be made monodisperse,24 and using synthetic materials in vivo also 
raises the concern of toxicity as heavy metals and organic solvents are common residuals 




Expressing recombinant protein through molecular biology presents a powerful 
alternative. Molecular biology is able to achieve precise gene modification, and therefore 
able to insert functionalization anywhere in a protein molecule. The precise gene 
modification also results in monodisperse molecular weights and gives product materials 
uniform quality, which chemically synthesized polymers cannot achieve perfectly. 
Within this thesis, we use the naturally occurring oleosin as the starting template, which 
is discussed in detail in the following section.  
 
1.2 Oleosin  
 
To address issues of biocompatibility, monodispersity, and functionalization, our 
laboratory has been assembling materials from recombinant oleosin and its variants. 
Oleosin is a group of naturally occurring structural proteins found across a wide range of 
oil-rich plants (maize, sesame, soybean, sunflower and etc.).27,28 Oleosin molecules from 
various plant sources all share a similar triblock structure with a central hydrophobic 
domain, and two hydrophilic arms at the N- and C-termini.27 The amphiphilicity of 
oleosin makes it a natural surfactant that functions to stabilize oil bodies in plant seeds.29 
Our laboratory demonstrated that recombinant oleosin and truncation variants thereof can 
self-assemble into different structures including micelles, fibers, sheets, and vesicles, 
depending on the architecture of the oleosin and ionic strength of the buffer.30 Because 
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oleosin is made recombinantly, it is possible to precisely control the amino acid 
sequence, and to insert bioactive sites anywhere in the oleosin molecule. Previously, the 
Hammer Lab has demonstrated that a bioactive motif RGDS added to the C-terminus of 
oleosin can increases the uptake by Ovcar-5 cells by 3-fold.31 Additionally, Her2/neu 
affibody fused to the N-terminus of the oleosin 30G variant can stabilize and target 
superparamagnetic iron oxide nanoparticle (SPIO)-loaded micelles to a Her2/neu+ cell 
line (T6-17 cells).32 Oleosin is a promising biomaterial that has plenty of potential yet to 
be studied.  
 
 
1.3 Description of Thesis 
 
 
This work addresses the potential of building smart drug carriers from recombinant 
oleosin. Oleosin has a unique triblock structure which is rarely found in natural surfactant 
proteins, and offers itself as a versatile platform where numerous motifs can be 
engineered towards a wide range of applications.27,29,33 In this work, we attempt to merge 
the existing knowledge of oleosin self-assembly structures and integrin mediated cell 
behavior, and create variants of oleosin that self-assemble into nanoscale carriers that can 
be targeted towards specific cell lines. The specific aims of this work are as follows: 
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1. Create a recombinant oleosin that is bioactive and answers to an environmental 
cue in physiological conditions 
2. Encapsulate an anti-cancer drug in self-assembled oleosin nanostructure, and 
achieve enhanced cell killing 
3. Create oleosin drug carriers that specifically target a family of receptors 
 
This work is composed of five chapters. This chapter provides an overview of current 
drug carriers, previously established knowledge of oleosin, and briefly describe the 
techniques used to complete this work.   
 
Chapter 2 of this work presents the construction of a oleosin variants that was 
engineered to have dual control over cellular uptake. This variant was built to have the 
bioactive motif RGDS protected by 20 amino acid that could be cleaved off by thrombin, 
and achieved RGDS 74% bioactivity shield in 15 hours on breast cancer cells. This work 
demonstrated that a single recombinant oleosin molecule can be engineered to be both 
bioactive and protease sensitive, and gave rise to multiple directions where this research 
can be carried further.  
 
Chapter 3 of this work took the previous results further by exploring the effects of 
synergy ligand PHSRN and a cell-penetrating peptide HIV-1 Tat with different local 
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ligand concentrations via oleosin blending. The oleosin variants has been shown to 
successfully encapsulate an anti-cancer drug, paclitaxel, and achieve enhanced breast 
cancer cell killing in a short as 3 hours. This work expanded our knowledge in the 
capability of using oleosin as drug carriers. 
 
Chapter 4 of this work explored outside the RGDS motif and breast cancer cell lines, 
and proved oleosin as an effective carrier on delivering paclitaxel into non-small cell lung 
cancer cells.  
 
Finally, Chapter 5 details the major conclusions and future directions of this work. Here, 
we discuss the next steps of engineering oleosin towards drug delivery and other 
therapeutic applications. There exists extensive knowledge on bioactive motifs ready to 
be merged with the oleosin model, and make oleosin an outstanding and universal 







To facilitate the reader’s understanding, this section offers background of frequently 
mentioned terms and concepts throughout this thesis. 
 
1.4.1 Paclitaxel and Nanoparticles 
 
Paclitaxel (PX) is a chemical isolated from the bark of Pacific Yew, and is one of the 
most effective chemotherapeutic so far and is mainly used to treat lung, ovarian and 
breast cancer. 16,34–36 Paclitaxel is a mitotic inhibitor that stabilizes microtubules. It 
inhibits the G2 and M phases of cell cycle and disrupt cell division, thereby causing cell 
death. 35,36 
 
Despite the effectiveness of paclitaxel as an anti-cancer drug, it also has several 
drawbacks. First, PX is an irritant that causes inflammation of veins that it’s administered 
through, and low blood count is a common side effect from PX that can lead to 
infection/anemia in patients. Second, PX has a low water solubility (~ 0.4 µg/mL) and 
need to be formulated in organic solvents such as a mixture of polyexyethylated castor oil 
and dehydrated ethanol, and those organic solvents is known to cause serious side effects 
such as hypersensitivity, as well as altering the pharmacokinetics of PX.36 Last but not 





Extensive efforts has been made in hope to enhance the solubility of PX and 
decrease systematic side effects, and over the years nanoparticles have emerged as a 
promising strategy. Nanoparticles as drug carriers of paclitaxel can be polymeric 
nanoparticles, albumin nanoparticles, lipid-based nanoparticles, emulsions, drug-polymer 
conjugates, metal nanoparticles, carbon nanotubes, and several other constructs.37 Some 
important nanoparticle-based paclitaxel delivery systems are discussed here.  
 
Poly (lactic-co-glycolic acid) (PLGA) Nanoparticles: PLGA is one of the most widely 
used biodegradable co-polymers investigated for nano-delivery systems, with a minimal 
systemic toxicity.37 PX-loaded PLGA demonstrated enhanced cytotoxicity in various 
cancer cell lines such as glioma C6, human non-small cell lung cancer (NCI-H69), HeLa 
cells, and transplantable liver tumors.14,37,38 The release of PX from PLGA nanoparticles 
can be slowed down by coating nanoparticles with chitosan.37 
 
Poly (Ethylene Glycol)-Phophatidyl Ethanolamine (PEG-PE) Nanoparticles: PEG-PE 
polymeric micelles developed by the Torchilin group presents two hydrocarbon chains in 
PE and achieved better stability of the micelles.2,37 PX-loaded PEG-PE micelles shoed 





Liposomes: Yoshizawa and colleagues formulated PX into liposomes composed of 
cholesterol, PEG-DSPE2000, and hydrogenated soybean phophatidylcholine (HSPC), 
which showed significantly improved antitumor efficiency in colon-26 solid tumor-
bearing mice.37 EndoTAG-1 is a PX-loaded cationic liposome developed by MediGene, 
and binds to negatively charged endothelial cells in tumor blood vessels. EndoTAG-1 
significantly decreased tumor size in a prostate cancer mouse model, and a combination 
of EndoTAG-1 and gemcitabine inhibited pancreatic metastasis in an orthotopic 
pancreatic cancer model.37      
 
Gold Nanoparticles: Gibson et al. demonstrated that PX can be coated to phenol-
terminated gold nanoparticles with a hexaethylene glycol linker.39 A gold/chitosan 
nanoparticle dispersed with PX, as described by Oh et al., can achieve sustainable release 
over a 12-day period with minimal initial burst release.40 Heo and co-workers presented a 
complex PX-functionalized gold nanoparticle system where PEG served as an anti-
fouling shell, biotin as a targeting ligand, and rhodamine B as a fluorescence probe.41 
This PX system demonstrated enhanced cytotoxicity in cancer cell lines including HeLa, 
A549, and MG63.41 
 
Nanoparticles have several other advantages as drug carriers, depending on the 
specific material and construct. The aqueous solubility of PX can be significantly 
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increased when it is conjugated with water-soluble polymers or encapsulated by 
lipids.14,38,42  The size of nanoparticles, usually several hundred nanometers in diameter, 
enables the preferential delivery of PX into tumor site due to the enhanced permeability 
and retention (EPR) effect.37,43,44 However, the targeting effect of nanoparticles is limited 
due to the challenge of conjugating bioactive peptide ligands on polymers, lipids, or 
metal nanoparticles, while conjugating or encapsulating the drug.  
 
1.4.2 Bioactivity from Fibronectin 
Fibronectin (FN) is a glycoprotein of the extracellular matrix that binds to integrins.45 FN 
have multiple forms as a result of alternative splicing of a single pre-mRNA, and usually 
exists as a dimer composed of two identical subunits ~250 kDa covalently linked by a 
disulfide bonds.46 It plays critical roles in a variety of cell activities such as cell adhesion, 
migration, growth and differentiation, and is therefore widely studied in the past two 
decades.  
Previously, researchers have narrowed down the regions involved in cell adhesion 
to several short integrin-recognition sequences. The most studied short sequence is RGD 
located in the 10th domain of FN. The RGD (Arg-Gly-Asp) sequence is the cell 
attachment site of a large number of adhesive extracellular matrix, blood, and cell surface 
proteins.47 It is recognized by nearly half of the over 20 known integrins in human body, 
especially the αβ family integrins.48 Due to its short nature, RGD is often incorporated 
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into drug and drug carrier design, and has shown enhanced cell uptake in systems such as 
polymers, lipids, and metal nanoparticles.48–53 
A second sequence PHSRN, found in the 9th domain of FN, acts in synergy with 
RGD by binding to a non-overlapping site on the α5 integrin and strengthen RGD 
binding.45,48 The synergy effect is heavily dependent on the spatial orientation and 
distance between RGD and PHSRN sequences, and previous research have suggested that 
the synergy effect is usually maximized by mimicking the natural distance of 30-40Å 




Chapter 2. Protease-Triggered, 
Integrin-Targeted Cellular Uptake 






Targeting nano-particles for drug delivery has great potential for improving efficacy and 
reducing side effects from systemic toxicity. New developments in the assembly of 
materials afford the opportunity to expose cryptic targeting domains in tissue-specific 
microenvironments in which certain proteases are expressed. Here, recombinant proteins 
are designed to combine the responsiveness to environmental proteases with specific 
targeting. Materials made recombinantly allow complete control over amino acid 
sequence, in which each molecule is identically functionalized. Previously, oleosin, a 
naturally occurring plant protein that acts as a surfactant, has been engineered to self-
assemble into spherical micelles - a useful structure for drug delivery. To make oleosins 
that are locally activated to bind receptors, oleosin is genetically modified to incorporate 
the integrin-binding motif RGDS just behind a domain cleavable by thrombin. The 
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resulting modified oleosin self-assembles into spherical micelles in aqueous 
environments, with the RGDS motif protected by the thrombin-cleavable domain. Upon 
the addition of thrombin, the RGDS is exposed and the binding of the spherical micelles 
to breast cancer cells is increased 4-fold.  
 
2.1 Introduction 
Targeting has the potential to reduce harmful systemic side effects of drug delivery. 
Additionally, positive results have been found where materials such as polymers, 
peptides, and nanoparticles are designed to become bioactive only in the presence of 
environmental cues, such as ligand/receptor concentration, the activity of enzymes, pH, 
temperature, magnetic field, and ultrasound.57–61 However, the development of synthetic 
materials that incorporate specific targeting is limited by stability of the carrier, 
reproducibility, and particle size control.24 Recombinant proteins present an attractive 
strategy for addressing many of the issues in biocarrier design. Recombinant proteins are 
monodisperse, can self-assemble into a variety of nanostructures, and be equipped with 
sensitivity to environment through sequence design.9,61,62 The manipulation of the amino 
acid sequence is made possible through molecular biology, where DNA sequence is 
designed to precisely alter the sequence of amino acids.  
 
Our laboratory has been assembling materials from recombinant oleosin and its 
variants.31,32 Oleosin is a group of naturally occurring structural proteins found across a 
15 
 
wide range of oil-rich plants (maize, sesame, soybean, sunflower and etc.).27,28 Oleosin 
molecules from various plant sources all share a similar triblock structure with a 
hydrophobic domain at the center, and two hydrophilic arms at the N- and C-termini.27 
The amphiphilicity of oleosin makes it a natural surfactant that functions to stabilize oil 
bodies in plant seeds.29 Our laboratory demonstrated that recombinant oleosin and 
truncation variants thereof can self-assemble into different structures including micelles, 
fibers, sheets, and vesicles, depending on the architecture of the oleosin and ionic 
strength of the buffer.30 In this paper, we focus on a subset of oleosins in which the 
internal hydrophobic core has been trimmed to 30 amino acids, and several large bulky 
hydrophobic residues have been replaced by glycines. We call variants that contain this 
sequence the  -30G- family. These molecules have been shown to self-assemble into 
spherical micelles with CMCs in the micromolar range.31  Micellar structures are 
attractive drug carriers – they can encapsulate insoluble drugs, have long circulation 
times in body, and protect the hydrophobic drugs from biological surroundings.11  
 
A common approach for targeting a cell line with a nanocarrier is to functionalize 
the carrier with a ligand that binds a cell-surface receptor. The RGDS motif is widely 
used for biomedical applications; it is present in fibronectin and other extracellular matrix 
proteins, and is recognized by many known integrins.63–65 RGDS has been studied for its 
effects on cell adhesion and internalization when incorporated with polymers and 
peptides, and promising results have been seen in studies where RGD is used to target 
nanocarriers to cancer cells.12,31,48,51,66–70 Most previous studies have focused on 
covalently linking the RGD tag to synthetic polymers and nanoparticles. However, using 
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synthetic materials in vivo raises the concern of toxicity as heavy metals and organic 
solvents are common residuals from their synthesis.25,26  
 
Another approach in targeted drug delivery is to use enzyme-sensitive carriers. It 
has been found that specific enzymes have abnormal expression profiles near 
pathological sites, such as cancer and inflammation.71 This abnormality can be exploited 
to achieve enzyme-triggered release from liposomes and nanoparticles.57,72–74 For 
example, thrombin (also known as coagulation factor II) is a serine protease that has 
important roles in hemostasis and blood coagulation. Aside from its functions in 
hemostasis, thrombin is known to induce invasion and metastasis in various cancers.75–77 
Therefore, using a thrombin-sensitive material as a drug carrier may be a promising way 
to enhance targeted cancer therapy. The thrombin cleavage site has been identified to be a 
short peptide sequence (LVPR|GS) that can be easily incorporated into the chain of an 
oleosin molecule, make the molecule sensitive towards thrombin proteolytic reaction.  
 
To improve from previous research, here we present an approach to design and 
engineer a recombinant version of oleosin, which self-assembles into micelles and 
exhibits integrin-binding activity only under the specific cue of thrombin reaction, and 
therefore giving us greater control over targeting and drug delivery. The naturally 
occurring protein surfactant oleosin was mutated to incorporate both the bioactive motif 
RGDS and thrombin cleavable sites, where the RGDS motif was placed behind the 
thrombin cleavable domain and protected from interacting with cell surface unless 
activated by thrombin. This multifunctional recombinant protein assembles into spherical 
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micelles, and targets cells overexpressing αvβ3  most avidly in the presence of thrombin. 
This multiple specificity enables both dynamic and regional control of cell binding, and 
may be of potential in developing a highly specific targeted cancer therapy.  
 
 
2.2 Materials and Methods  
2.2.1 Protein Design and Expression  
Genetic modification on the previous oleosin-30G(-) was done through PCR and the 
genes were inserted into the expression vector pBamUK and later transformed into the 
BL21 (DE3) strain of E. coli for expression. DNA sequencing was performed before 
protein expression by the E. coli strain BL21 DE3 (Stratagene) controlled by the lac 
promotor on the pBamUK. Cultures are grown at 37°C in Luria Broth (LB) with 50 
μg/ml kanamycin until OD600 reaches 0.6. Isopropyl β-D-thiogalactoside (IPTG) was 
added to the culture to a final concentration of 1.0 mM to induce the expression of 
oleosin. Cells were collected by spinning down the culture at 15,000g for 15min and were 
kept frozen at -20°C until purification. pBamUK adds a 6-histidine tag to the C-terminus 
of oleosin molecule which facilitates  purification through immobilized metal affinity 
chromatography (IMAC). All variants of proteins in this study express solubly. Yields for 
all variants in this study were ~80-100 mg of purified protein per liter of culture. All four 




All oleosin strands in this project have 6-Histidine tag to the C-terminus and were 
purified with Ni-NTA columns (Pierce). All protein strands in this study are soluble and 
can be purified with the protocol suggested by Vargo et al.31 In brief, frozen protein pellet 
was re-suspended in B-PER Bacterial Protein Extraction Reagent (Fisher). After spinning 
down at 15,000g for 15min, the supernatant was left to bind with the Ni-NTA resin for at 




2.2.2 Protein Characterization 
 
SDS-PAGE: To determine the purity of protein samples, purified oleosin samples were 
loaded on NuPAGE Novex 4-12% Bis-Tris mini gels (Invitrogen) in 2-(N-morpholino)-
ethanesulfonic acid (MES) buffer. SimplyBlue SafeStain (Invitrogen) was used to stain 
the gel following electrophoresis. The gel was imaged with a Kodak Gel Logic 100 
imaging system. 
 
Mass Spectroscopy: To prepare matrix solution, sinapinic acid was added to 50:50 (v/v) 
ACN: [0.1 vol.% TFA in water] to a final concentration of 10mg/ml. 0.5 μL of matrix 
solution was added to Bruker AnchorChip, immediately followed by 0.5 μL of oleosin 
solution. Solutions were mixed on the AnchorChip using a pipet tip and air-dried. 
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Samples were analyzed with matrix-assisted laser desorption ionization (MALDI) mass 
spectroscopy (Bruker, PennChemistry Mass Spectrometry Facility).   
 
Circular Dichroism (CD) : An AVIV 410 spectrometer (AVIV Biomedical, Inc.) was 
used to collect UV CD spectra at 25°C in a 1 mm quartz cell. The protein sample 
concentration was 10 μM in 50 mM phosphate and 140 mM NaF. The CD data was 
analyzed with the CDSSTR algorithm using Dichroweb. 
 
Critical Micelle Concentration (CMC) - Pyrene Assay : The critical micelle 
concentration (CMC) was determined by pyrene assay, where pyrene was used as a 
fluorescence probe that prefers non-polar environments.78 The ratio of the first and third 
peaks of the emission spectrum (I1/I3) decreases as a function of polarity of the protein 
sample solution (Figure 2.10), and this ratio is considered as an index of polarity in the 
environment.78–80 The pyrene assay data were fit with a sigmoidal Boltzmann equation 
(SBE) suggested by Aguiar et al, and the CMC value is determined to be the inflection 
point.81  
                                                 (1) 
where x is the concentration of protein, ai and af are initial and final asymptotes of the 
sigmoid respectively, x0 is the center of the sigmoid and Δx is the interval of x.
82 It has 
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been suggested that the for curves with the ratio x0/ Δx<10, the CMC will be the 
concentration at the inflection point.  
7 μL of 12 mM pyrene (Sigma-Aldrich, St. Louis, MO) in ethanol (200 Proof) was added 
to 20ml of PBS. Protein samples were prepared by serial dilution from the high-
concentration protein stock to as low as 0.001 μM. In each low-volume cuvette, 600 μL 
of protein sample and 100 μL of pyrene in PBS solution were added. Samples were 
excited at 334 nm and the emission spectrums were collected at 360-400 nm (excitation 
slit, 8nm; emission slit, 2nm) using a Fluoromax-4 spectrophotometer (Horiba Jobin 
Yvon). The ratio of intensities of the first and third peaks (I1/I3) was plotted as a function 
of protein concentration. The inflection point of the best-fit sigmoidal curve was 
determined to be the CMC.  
 
Dynamic Light Scattering (DLS): 700 μL of protein sample was added to a small-
volume cuvette cleaned with compressed air. DLS was performed with a Malvern 
Zetasizer Nano ZS (Westborough, MA). 
 
Thrombin Reaction: Thrombin cleaving reaction was performed with Human Thrombin 
(Haematologic Technologies Inc., HCT-0020, Essex Junctions, VT) using the protocol 





Oleosin Labeling: Oleosin was labeled with 10 molar-fold excess of amine-reactive 
fluorophore Dylight 488 NHS-ester (Thermo Scientific) according to manufacturer’s 
protocol. Excess dye was removed by repeated dialysis against PBS until background 
fluorescence was undetectable.  
2.2.3 Mammalian Cell Culture and Cellular Uptake Study 
 
Cell Culture: The human breast cancer cell line MDA-MB-231 (ATCC HTB-26) was 
acquired from the University of Pennsylvania Cell Center. MDA-MB-231 cells were 
cultured in RPMI 1640 (Life Technologies 22400, Carlsbad, Ca) supplemented with 10% 
heat-inactivated fetal bovine serum (Sigma Aldrich F2442, St. Louis, MO) and 100 
units/ml penicillin and 100 μg/ml streptomycin (Life Technologies 15140) on tissue-
culture treated plastic in a 37°C humidified incubator with 5% CO2.  
 
Targeted Cellular Uptake: When MDA-MB-231 cells reach 60-70% confluency, the 
growth media was aspirated and the cell culture was triple washed and left in RPMI 1640 
without phenol red (Life Technologies 11835). Labeled oleosin micelle solution was 
added to the cell culture to a final concentration of 10 μM. After the internalization 
period (3-15hrs), the cell culture was triple washed with RPMI 1640 media (no phenol 
red). When testing the cellular uptake levels of the thrombin-cleaved versions of oleosin-
Throm-RGDS-30G(-) and oleosin-Throm-RADS-30G(-), the variants were fully cleaved 




Cell Fixing and Membrane Staining: Following internalization, the cell culture was 
fixed with fixed with 4% PFA and cell membrane was labeled with Wheat Germ 
Agglutinin - Alexa Fluor 633 Conjugate (Invitrogen W21404), using the protocol 
provided by the manufacturer.  
 
2.2.4 Cellular Uptake Visualized by Confocal Microscopy  
 
Confocal Microscopy: Cell cultures were imaged with a Leica TCS SP5 confocal 
microscope (Bioengineering Confocal and Multiphoton Imaging Core Facility, UPenn). 
Fixed cell cultures on a tissue-culture treated surface were directly imaged with a HCX 
IRAPD L 25x/0.95 W dipping lens. Dylight 488 and Alexa Fluor 633 were excited using 
10% strength Argon laser and HeNe laser, respectively. Images were acquired at 400 Hz 
scanning frequency at slice thickness of 296.40 nm. Gain was set to be 749.9 V and 777.1 
V for the 633 and 488 channels, respectively. Offset was kept at 0.0% for all acquisitions.  
 
Quantification of Oleosin Uptake: From the z-stack images taken for each sample, 5 
images were chosen at 5 μm apart in vertical depth. Total number of cells was counted, as 
well as cells with fluorescence from labeled oleosin inside the cell membrane. If a cell 
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has only oleosin micelle adhering to the cell surface, it was not included for the purpose 
of quantifying cellular uptake.  
 
 
2.3 Results and Discussions 
2.3.1 Oleosin Design, Self-Assembly and Secondary Structure  
It has been demonstrated that the naturally occurring 20 kDa wild-type sunflower seed 
oleosin can be widely modified.30–32 Previously, oleosin-30G(-) was designed from the 
wild-type sunflower seed oleosin by: (i) truncating 57 amino acid out of the hydrophobic 
block to remove hydrogen bridges; (ii) adding five glycines into the hydrophobic block to 
increase flexibility; and (iii) mutating the hydrophilic arms to contain only negatively 
charged amino acids to improve protein expression.31  
 
In this current study, four further variants were created from oleosin-30G(-). 
Previously, we demonstrated that the addition of the RGDS tag to the C-terminus of 
oleosin can increase the uptake by Ovcar-5 cells by 3-fold.31  Two of these are controls. 
A positive control oleosin-RGDS-30G(-), contains an integrin-binding motif RGDS to 
the N-terminus of oleosin-30G(-). A second molecule, oleosin-RADS-30G(-), contains a 
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non-active peptide sequence RADS (Arg-Ala-Asp-Ser) at the same location to serve as a 
negative control (Figure 2.1 A).  
 
 
Figure 2.1. Molecular view of Oleosin-30G(-) variants. (A) Illustrations depicting 
addition of motifs RGDS (yellow) and RADS (orange) to the variants Oleosin-RGDS-
30G(-) and Oleosin-RADS-30G(-), respectively. (B) Oleosin-Throm-RGDS-30G(-) is 
mutated from Oleosin-RGDS-30G(-) where the RGDS motif  is moved  to the center of 
the N-terminus hydrophilic arm and protected by a thrombin cleavable domain (green). 
Another thrombin cleavable domain is added to the C-terminus hydrophilic arm so that 
the remaining protein molecule have two hydrophilic arms similar in length after the 






Since it would be beneficial to have greater dynamic control over targeting, we 
designed two additional oleosins that can target cells in a protease-triggered manner. To 
achieve this, oleosin-Throm-RGDS-30G(-) was designed to incorporate a thrombin 
cleavable domain (LVPR|GS) on the N-terminus hydrophilic arm, followed by a RGDS 
motif which is only exposed when the oleosin molecule is cleaved by thrombin (Figure 
2.1B and Figure 2.2). Another thrombin cleavable domain is added in the C-terminus 
hydrophilic arm such that the N- and C-terminus hydrophilic arms remain at 
approximately equal lengths after the thrombin cleavage reaction. Similarly, oleosin-
Throm-RADS-30G(-) was designed as a negative control that contains the non-targetable 
motif RADS (Figure 2.1 B). We show that these molecules self-assemble into micelles 
and can be used to target a cancer cell line in a highly controllable manner.  
 
 
Figure 2.2. Micellar view of Oleosin-Throm-RGDS-30G(-). When in aqueous solution 
above its critical micelle concentration, the molecules self-assembly to micelles by 
collapsing hydrophobic blocks (red) together surrounded by the hydrophilic arms (blue). 
After thrombin cleaves the hydrophilic arms at the thrombin cleavable sites (green), the 
RGDS motif will be exposed at the N-terminus end of the hydrophilic arm. Oleosin-





To monitor the purity of the recombinant protein samples and ensure that the 
protein has the exact peptide sequence as designed, SDS-PAGE and MALDI-TOF tests 
were carried out for each sample after purification (see Supporting Information). Both 
assessments show that recombinant proteins are highly purified and are monodisperse. 
Since self-assembly into a micellar structure is critical for carrying a drug, the critical 
micelle concentration (CMC) for each construct was determined using a pyrene assay. 
Dynamic light scattering (DLS) was used to verify that the oleosin molecules self-
assemble into micelles above the CMC (Figure 2.3). Measurements were taken at 10 μM, 
above the CMC value for all variants. Oleosin-Throm-RGDS-30G(-) is designed to be 
protease-sensitive, where the presence of thrombin results in the cleaving of both 
hydrophilic arms and the exposure of the bioactive RGDS motif. MALDI-TOF-MS was 
used to check the effect of thrombin cleaving reaction, and the resulting molecular weight 
was as expected. DLS confirmed that the cleaved product still self-assembles to micelles 
at 10 μM (Figure 2.3), and the thrombin cleaving reaction results in a 4 nm decrease in 
the hydrodynamic diameter of the spherical micelle. Molecular weight, CMC, and 
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Figure 2.3. Micellar structures for all variants above their CMC were confirmed with 
DLS. All protein variant not cleaved by thrombin show a similar hydrodynamic diameter 





Figure 2.4. (A) CD spectra of all oleosin variants at 10 μM. (B) Comparison of CD 
spectra on Oleosin-Throm-RADS-30G(-) and Oleosin-Throm-RGDS-30G(-) before and 
after cleaved by thrombin. (C) CDSSTR analysis of the CD spectrum data that shows 40-
50% of the secondary structure for all oleosin variants is unordered. The remaining 
oleosin molecules after thrombin cleaving reaction show relatively higher contents of 









The goal of this study is to explore the effect of integrin-binding motifs and 
protease cleavable sites on cell binding and uptake, and thus it is desirable for all protein 
variants to have similar secondary structures to minimize variation due to secondary 
structure. The secondary structure of proteins was elucidated with circular dichroism 
(CD) (Figure 2.4A). The spectrum data were analyzed with the CDSSTR algorithm on 
Dichroweb (Figure 2.4C).83,84 When inserted at the same location, the motifs RADS and 
RGDS do not alter the overall secondary structure of the oleosin molecules. Both oleosin-
RADS-30G(-) and oleosin-RGDS-30G(-) have a similar construct of ~40% unordered 
structure, ~20% β-sheet, ~30% turn, and <10% α-helix structure. The addition of 
thrombin cleavable domains only caused slight changes in the percentages of unordered 
and β-sheet structures: unordered structure increased by 5% and β-sheet structure 
decreased by 3%, whereas the percentages of turn and α-helix are roughly unchanged. 
The secondary structures of all protein variants in this study are very similar, suggesting 








2.3.2 Integrin Mediated Oleosin Micelle Uptake by Breast 
Cancer Cells 
 
The MDA-MB-231 cell line, a human breast cancer cell line that has been shown to 
upregulate the RGDS binding integrin αvβ3 
63,85,86, was chosen to test the in vitro cell 
uptake of recombinant oleosin variants. After the breast cancer cell culture reached 60-
70% confluency, DyLight-488 labeled protein micelles were introduced to the cell culture 
media at 10 μM. Protein micelles were allowed to interact with cells at 37 °C for 3, 6, 9 
and 15 hours before unbound material was washed away. Cells were immediately fixed 
and labeled with fluorescently-tagged wheat germ agglutinin to visualize the cell 
membrane. Due to the unique advantage of producing images from a single focal plane, 
confocal microscopy was chosen over wide-field to visualize the uptake of oleosin 
micelles by breast cancer cells (Figure 2.5). For drug delivery, it is desirable to have the 
protein micelles being internalized by breast cancer cells, as opposed to attaching to the 
cell surface. To investigate the location of the protein micelles, a z-stack analysis was 
done by taking images at a z-step size of 0.5 μm for a total thickness of 30 μm for all 
samples. Each image reflects fluorescence signals coming from one focal plane. An 
example z-stack imaging series after a 15hr uptake of oleosin-RGDS-30G(-)is shown in 
Figure 2.6 where image from a horizontal focal plane is shown at every 5 μm. The 
results indicate that the majority of the fluorescence comes from inside the breast cancer 
cells, while in some rare instances the protein micelles stayed adhered to the cell surface 
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after repeated washing and were crosslinked to the cell surface during the cell fixing step. 
This observation could mean that cellular uptake is rapid once protein micelles adhere to 
the cell surface, or that the adhered protein micelles were washed off prior to the fixation 
step.  
 
The level of cellular uptake was quantified by comparing the percentage of cells 
with fluorescence signal from labeled oleosin (Figure 2.7). For the purpose of 
quantifying the oleosin micelles being internalized as opposed to adhering to the cell 
surface, only cells with fluorescence signals inside the cell were included for analysis.  
 
First, the addition of the bioactive RGDS motif showed significantly increased 
uptake, when compared to the non-active RADS motif. After 3 hours of incubation, 
internalization levels of all oleosin variants were similar, with an average percentage of 
fluorescent cells at 9.1%. Following longer incubation periods, the internalization of the 
negative control oleosin-RADS-30G(-) slowly increased, until 16% fluorescent cells were 
labeled after 15 hours of incubation. However, the structurally similar, but the positive 
control which contained RGDS, oleosin-RGDS-30G(-), showed a significantly faster 
increase in cell internalization as a function of incubation time. Compared to the negative 
control, oleosin-RGDS-30G(-) increased cell internalization by factors of 1.8, 3.3 and 4.6 
at 6, 9, and 15 hours of incubation time, respectively. Similar trends were observed when 
comparing the uptake of versions of oleosin-Throm-RGDS-30G(-) after thrombin 
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cleavage and the corresponding negative control containing RADS. The increased uptake 
facilitated by the RGDS motif, compared to the RADS motif, indicates that the specific 
sequence of recombinant oleosin is essential in this study. We show that the RGDS motif 
can be successfully engineered into oleosin molecules and exhibits significant bioactivity 
in the self-assembled spherical micelle form. A single RGDS motif added on each oleosin 
molecule is able to effectively increase the cellular uptake of protein micelles. Oleosin-
RGDS-30G(-) is demonstrated to be a recombinant protein material that can self-
assemble, target breast cancer cells by increasing the cellular uptake.  
 
To improve on previous research, here we illustrate the effect of protease-
triggered cell uptake by comparing the performances of oleosin-Throm-RGDS-30G(-) 
and its cleaved form. Compared to the RGDS motif being protected, cleavage by 
thrombin demonstrated a clear advantage in cell uptake starting at 6 hours of incubation. 
After 15 hours of incubation, the exposure of the RGDS after thrombin cleavage led to a 
4.2x increase in cell internalization compared to the non-active RADS control.   
 
When comparing the uptake levels between oleosin-Throm-RGDS-30G(-) and its 
RADS control, it appears that the 24 amino acid peptide on the hydrophilic arm did not 
completely shield the RGDS motif from making contact with the cell surface. The 
protected RGDS motif led to similar cellular uptake levels compared to the negative 
control at 3 hours of incubation, but showed a two-fold increase in uptake at both 9 hours 
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and 15 hours of incubation. This observation suggests that when in a micelle, the 
hydrophilic arms of oleosin are flexible and highly solvated into the surrounding aqueous 
environment, thus allowing the embedded bioactive RGDS to come in contact with cell 
surface integrin receptors. However, 72% of the activity attributed to the RGDS motif is 
still shielded by the protection of 27 amino acids, and can only be released after thrombin 
activity, thereby offering greater control over the integrin-binding activities.  
 
These results demonstrate that the oleosin-Throm-RGDS-30G(-) is a successful 
construct whose integrin-binding activity is triggered by a specific protease thrombin, and 
that oleosin is a valuable model for engineering responsive materials for targeted drug 
delivery applications. Aside from the ability of recombinant proteins to incorporate 
bioactive motifs, recombinant protein can also be conjugated with clinically proven drugs 
to increase tumor-specific uptake38,56,70. Recently, Bhattacharyya et al. demonstrated that 
the hydrophobic drug paclitaxel can be conjugated with recombinant chimeric 
polypeptides that self-assemble into nanoparticles, and resulted in increased systemic 
exposure of paclitaxel38. Nanoscale micelles can be readily made with multiple variants 
of recombinant protein surfactants each presenting its own bioactive moieties (e.g. cell 
targeting, imaging, therapeutics)70,87, and are thus able to achieve both high specificity 
and direct applications. We believe the recombinant oleosin model offers much future 





Figure 2.5. In vitro confocal 
microscopy images of  
DyLight 488 labeled oleosin 
micelle solutions uptake in 
MDA-MB-231 cells 
incubated at 37°C for 15 
hours. Scale bars are 100 μm 
for all images. Cells were 
fixed with 4% PFA and 
labeled with Alexa Fluor 633. 
Images from the 488 nm 
channel, 633 nm channel, and 
merged channels were shown 
in panels A, B, and C, 
respectively. Cell membrane 
is shown as red and oleosin 









Figure 2.6. Confocal microscopy images for z-stack analysis same sample: Oleosin-
RGDS-30G(-) on MDA-MB-231 cells, incubated for 15 hours under 37 °C. All scale bars 
represent 20 μm. Each image reflects fluorescent signals coming from one specific focal 
plane. Most protein micelles are internalized in breast cancer cell, while in some 
instances oleosin micelles adheres to the cell surface after repeated washing after the 






Figure 2.7.  The addition of exposed RGDS led to a 4.6 times increase in cellular uptake 
over 15 hours, compared to the scrambled sequence of RADS. When RGDS motif was 
protected by 24 amino acids on the hydrophilic arm, increased uptake is observable 
starting from 9 hours of incubation where it showed 2.0 and 1.8 times increase at 9 hours 
and 15 hours, respectively. Oleosin-Throm-RGDS-30G(-), when fully reacted with 
thrombin, resembled very closely to Oleosin-RGDS-30(-) smaller in micellar size, and 
showed a similar 4.4 times increase in cellular uptake compared to Oleosin-Throm-











Figure 2.8. Mass spectra of (A) Oleosin-RADS-30G(-), (B) Oleosin-RGDS-30G(-), (C) 
Oleosin-Throm-RADS-30G(-), (D) Oleosin-Throm-RGDS-30G(-),(E) Oleosin-Throm-








Figure 2.9. SDS-PAGE gel image demonstrates that the protein products were highly 
purified after IMAC purification. Lane 1: Oleosin-RADS-30G(-); Lane 2: Oleosin-
RGDS-30G(-); Lane 3: Oleosin-Throm-RADS-30G(-); Lane 4: Oleosin-Throm-RGDS-
30G(-). All protein variants are highly charged and therefore the bands did not match the 







Figure 2.10. Pyrene assay results for all oleosin variants. The ratio of the first and third 
peaks of the emission spectrum (I1/I3) is plotted as a function of polarity of the protein 
solution. Data is fit with the SBE equation (Equation 1) and the inflection point is 
















In this study, we functionalized oleosin molecules to incorporate both integrin-binding 
motifs that could be activated by proteases. We have shown that adding the integrin-
binding motif RGDS to the end of the oleosin molecule significantly increases its 
internalization by a breast cancer cell line MDA-MB-231. In addition, we created a 
protease-sensitive oleosin, oleosin-Throm-RGDS-30G(-), in which the bioactive motif 
RGDS is only fully exposed by the specific protease thrombin. This construct of oleosin 
serves as a flexible template in which multiple functionalizations can be engineered into 
the same molecule to achieve highly specific, regulated cell targeting and dynamic 
control over localized binding. Apart from self-assembled micelles, as shown in this 
study, oleosin can also be engineered to self-assemble into other structures including 
sheets, worm-like micelles, and vesicles, giving a wide range of possible structural 
biomaterials, all of which can be modulated with different dynamic switches. 
Genetically-engineered oleosin offers an exciting platform in which combinations of 
multiple bioactive sites can be precisely engineered and integrated as a part of the self-
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Chapter 3. Enhanced Cell Killing 







Bioactive peptide ligands are effective and specific vectors that targets cell receptors, and 
have shown great potential as strategies for drug delivery. Conventional materials used as 
drug delivery matrices are chemically synthesized and difficult to functionalize, which 
compromises their capability in becoming smart drug carriers. Here, we present 
recombinant protein as a novel appoach to overcome these limitations. Previously, 
oleosin, a natural surfactant protein, has been engineered to self-assemble into spherical 
micelles and increase cellular uptake with a built-in RGDS motif. To enhance the cellular 
uptake performance and investigate the practicality of transforming oleosin from a 
surfactant to a drug carrier, oleosin is further genetically modified to incorporate a 
synergy peptide PHSRN and a cell-penetrating peptide HIV-1 Tat. The resulting 
modified oleosin variants retain the spherical micellar structure in aqueous environments, 
and can increase uptake by breast cancer cells by as much as sixfold compared to the 
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negative control. Upon encapsulation of an anti-cancer drug paclitaxel, oleosin drug 





In order for pharmaceutical agents to be safe and effective, the properties desired for drug 
carriers are that they are biodegradable, can target specific disease cells, and carry a 
therapeutic cargo.4–6 A variety of chemically synthesized materials including 
polymersomes, phospholipids, and dendrimers have been explored for their potential to 
construct smart drug carriers. Despite the promising results seen for conjugating cell 
targeting peptide sequences to these materials, the size and location of the bioactive 
inserts remained limited, and the uniform quality of synthesized product continued to be 
difficult to solve in practice.11,24,88,89   
 
Here we present an alternative strategy of designing recombinant protein towards 
smart drug carriers. Molecular biology provides the precise control over the amino acids 
in the end protein product, which gives full freedom in functionalizing a protein 
molecule, while simultaneously ensuring that all protein molecules are of the same size. 
Previously, our lab has established a library of recombinant protein variants from the 
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naturally occurring protein oleosin. Oleosin is a group of natural surfactants and has an 
unique triblock structure, where the hydrophobic domain is centered between two 
hydrophilic arms at the N- and C- termini.27 Our laboratory demonstrated that 
recombinant oleosin variants and self-assemble into different nanoscale structures 
including spherical micelles, worm-like micelles, sheets, and vesicles.30 A particular 
subset of oleosin (the -30G family) where the hydrophobic part was trimmed to 30 amino 
acids, self-assemble into nanoscale spherical micelles and was explored for its ability to 
target breast cancer cells. Previously, we have demonstrated that oleosin can be mutated 
towards drug delivery applications by creating a variant where the integrin-binding motif 
RGDS was only active when triggered by thrombin, and successfully increased cellular 
uptake in breast cancer cells.90 This work explores strategies to enhance the performance 
of oleosin internalization, and subsequent cell killing with an encapsulated anti-cancer 
drug paclitaxel.  
 
PHSRN (Pro-His-Ser-Arg-Asn) is a ligand found in the 9th type III domain of 
fibronectin, adjacent to the 10th domain that contains the RGD motif, and has been found 
to act synergistically with RGD to enhance cell adhesion and spreading.55,91,92 Previously, 
studies have been done to mimic the natural distance of 30-40Å between RGD and 
PHSRN by inserting various numbers of glycine as spacers.55,93,94 In a 2007 study done 
by Schmidt and Kao, it is found that the synergy is most noticeable when 13 glycines are 
added as interposition spacers.93 Most previous studies on PHSRN were done on PEG 
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and lipids, , and were limited by the purity of PEG/lipid-peptide ligand conjugates from 
peptide synthesizers. 49,54,94 
 
Besides targeting the disease cells to reducing systematic side effects, intracellular 
delivery of therapeutic molecules is another key problem in drug delivery. Many 
pharmaceutic agents require intracellular delivery to exert their therapeutic actions. For 
example, mitochondria, nuclei and lysosomes are intracellular targets for pro-apoptotic 
anticancer drugs.7,24,95  However, cell membranes prevent protein and nanoparticulate 
drug carriers from entering cells, as well as causing lysosomal degradation, unless an 
active transport mechanism is present. A promising approach to overcome cellular barrier 
was the discovery of cell-penetrating peptides (CPPs), where certain peptides can be 
tethered to drugs of interest and translocate across the plasma membrane. Tat peptide, a 
short sequence derived from the transcriptional activator protein encoded by human 
immunodeficiency virus type I (HIV-1), is a frequently used CPP that’s been shown to 
carry cargoes of various molecular weights.23,50,96–99 The limitations of current research 
on using Tat-peptide to enhance intracellular delivery are challenges in conjugating Tat-
peptide to drugs and drug carriers.  
To improve previous research, here we present several variants of oleosin 
enhanced by PHSRN bioactivity and a cell-penetrating peptide HIV-1 Tat, that self-
assemble into spherical micelles and are capable of carrying a drug payload. The 
naturally occurring protein surfactant oleosin was mutated to incorporate the bioactive 
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RGDS on one hydrophilic arm, with PHSRN or Tat-peptide on the other hydrophilic arm. 
This family of recombinant proteins can be blended at different ratios and are able to 
encapsulate an anti-cancer drug paclitaxel and achieve effective cell killing on breast 
cancer cells. This study demonstrates the potential for oleosin variants to have a major 
impact in the design of smart drug carriers.     
 
3.2 Materials and Methods  
3.2.1 Protein Design and Expression  
 
Oleosin Gene Construction and Expression: Genetic modification were purchased 
through Integrated DNA Technologies and the genes were inserted into the expression 
vector pBamUK and later transformed into the BL21 (DE3) strain of E. coli for 
expression. DNA sequencing was performed before protein expression by the E. coli 
strain BL21 DE3 (Stratagene) controlled by the lac promotor on the pBamUK. Cultures 
are grown at 37°C in Luria Broth (LB) with 50 μg/ml kanamycin until OD600 reaches 0.6. 
Isopropyl β-D-thiogalactoside (IPTG) was added to the culture to a final concentration of 
1.0 mM to induce the expression of oleosin. Cells were collected by spinning down the 
culture at 15,000g for 15min and were kept frozen at -20°C until purification. All oleosin 
variants presented in this study adds a 6-histidine tag to the C-terminus of oleosin 
molecule which facilitates  purification through immobilized metal affinity 
chromatography (IMAC). All variants of proteins in this study express solubly. Yields for 
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all variants in this study were within the range of 40-100 mg of purified protein per liter 
of culture. All oleosin variants were stable in buffered solutions (pH~7.4) for 4 weeks in 
4°C, and for at least 48 hours in 37°C. 
 
Protein Purification: All oleosin strands in this study have 6-Histidine tag to the C-
terminus and were purified with Ni-NTA columns (Pierce). All protein strands in this 
study are soluble and can be purified with the protocol suggested by Vargo et al.31 In 
brief, frozen protein pellet was re-suspended in B-PER Bacterial Protein Extraction 
Reagent (Fisher). After spinning down at 15,000g for 15min, the supernatant was left to 
bind with the Ni-NTA resin for at least 1 hour. Then the column was repeatedly washed 
and protein sample was eluted out.  
 
3.2.2 Protein Characterization 
 
SDS-PAGE: To determine the purity of protein samples, purified oleosin samples were 
loaded on NuPAGE Novex 4-12% Bis-Tris mini gels (Invitrogen) in 2-(N-morpholino)-
ethanesulfonic acid (MES) buffer. SimplyBlue SafeStain (Invitrogen) was used to stain 





Mass Spectroscopy: To prepare matrix solution, sinapinic acid was added to 50:50 (v/v) 
ACN: [0.1 vol.% TFA in water] to a final concentration of 10mg/ml. 0.5 μL of matrix 
solution was added to Bruker AnchorChip, immediately followed by 0.5 μL of oleosin 
solution. Solutions were mixed on the AnchorChip using a pipet tip and air-dried. 
Samples were analyzed with matrix-assisted laser desorption ionization (MALDI) mass 
spectroscopy (Bruker, PennChemistry Mass Spectrometry Facility).   
 
Circular Dichroism (CD): An AVIV 410 spectrometer (AVIV Biomedical, Inc.) was 
used to collect UV CD spectra at 25°C in a 1 mm quartz cell. The protein sample 
concentration was 10 μM in 50 mM phosphate and 140 mM NaF. The CD data was 
analyzed with the CDSSTR algorithm using Dichroweb. 
 
Critical Micelle Concentration (CMC) - Pyrene Assay : The critical micelle 
concentration (CMC) was determined by pyrene assay, where pyrene was used as a 
fluorescence probe that prefers non-polar environments.78 The ratio of the first and third 
peaks of the emission spectrum (I1/I3) decreases as a function of polarity of the protein 
sample solution, and this ratio is considered as an index of polarity in the environment.78–
80 The pyrene assay data were fit with a sigmoidal Boltzmann equation (SBE) suggested 




Dynamic Light Scattering (DLS): 700 μL of protein sample was added to a small-
volume cuvette cleaned with compressed air. DLS was performed with a Malvern 
Zetasizer Nano ZS (Westborough, MA). 
 
Oleosin Labeling: Oleosin was labeled with 10 molar-fold excess of amine-reactive 
fluorophore Dylight 488 NHS-ester (Thermo Scientific) according to manufacturer’s 
protocol. Excess dye was removed by repeated dialysis against PBS until background 
fluorescence was undetectable.  
 
Oleosin Blending: Oleosin were blended at 20 μM by gently mixing the micellar 
solutions, sonicating for 20 seconds, and let recover at room temperature for at least 10 
minutes. Blended samples were checked under DLS to verify self-assembly structure.  
 
 
3.2.3 Mammalian Cell Culture  
 
The human breast cancer cell line MDA-MB-231 (ATCC HTB-26) was acquired from 
the University of Pennsylvania Cell Center. MDA-MB-231 cells were cultured in RPMI 
1640 (Life Technologies 22400, Carlsbad, Ca) supplemented with 10% heat-inactivated 
fetal bovine serum (Sigma Aldrich F2442, St. Louis, MO) and 100 units/ml penicillin and 
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100 μg/ml streptomycin (Life Technologies 15140) on tissue-culture treated plastic in a 
37°C humidified incubator with 5% CO2. 
 
When MDA-MB-231 cells reach 60-70% confluency, the growth media was 
aspirated and the cell culture was triple washed and left in RPMI 1640 without phenol red 
(Life Technologies 11835). Labeled oleosin micelle solution was added to the cell culture 
to a final concentration of 10 μM. After the internalization period (3-15hrs), the cell 
culture was triple washed with RPMI 1640 media (no phenol red). 
 
Following internalization, the cell culture was fixed with fixed with 4% PFA and 
cell membrane was labeled with Wheat Germ Agglutinin - Alexa Fluor 633 Conjugate 
(Invitrogen W21404), using the protocol provided by the manufacturer. 
 
3.2.4 Cellular Uptake Study 
 
Confocal Microscopy: Cell cultures were imaged with a Leica TCS SP5 confocal 
microscope (Bioengineering Confocal and Multiphoton Imaging Core Facility, UPenn). 
Fixed cell cultures on a tissue-culture treated surface were directly imaged with a HCX 
IRAPD L 25x/0.95 W dipping lens. Dylight 488 and Alexa Fluor 633 were excited using 
10% strength Argon laser and HeNe laser, respectively. Images were acquired at 400 Hz 
52 
 
scanning frequency at slice thickness of 296.40 nm. Gain was set to be 749.9 V and 777.1 
V for the 633 and 488 channels, respectively. Offset was kept at 0.0% for all acquisitions.  
 
Flow Cytometry: Flow cytometry was performed on live cells with BD LSRII (Upenn 
FCCSRL) immediately following incubation time. Sample population of each run was 
kept at 10,000 cells. For every flow cytometry experiment, blank data was collected by 
running cell culture treated with PBS for all four time durations (3, 6, 9, and 15 hours). 
Then cell culture treated with RADS-30G(-) for the same four time durations were tested 
as negative controls. Negative control results were compared to historical data and 
experiment only proceeded when negative control error fell within 5%. Flow cytometry 
histogram was collected from each run and analyzed by FlowJo. Cellular uptake was 
quantified by first eliminating background signal measured by PBS blank, then taking the 
weighted average of fluorescence per cell.   
 
3.2.5 Paclitaxel Encapsulation 
 
Paclitaxel (ThermoFisher P3456) was resuspended in 200 proof ethanol and carefully 
injected into oleosin micellar solution at concentration of 20 μM. The mixture was then 
briefly sonicated for 20 seconds and let sit for 10 minutes in room temperature. The 
mixture was then dialyzed against PBS. Protein concentration was measured by 
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Nanodrop and adjusted to 10 μM. Each sample was verified to be in micellar solution 
form with Dynamic Light Scattering (DLS) before dosed onto cells. The encapsulation 
efficiency of paclitaxel by oleosin was measured with a labeled version of paclitaxel 
(ThermoFisher P22310). A calibration of paclitaxel fluorescence signal vs. concentration 
was established with a Fluoromax-4 spectrophotometer (Horiba Jobin Yvon), and the 
procedure described here resulted in a 3.21±1.2% encapsulating efficiency of paclitaxel. 
 
3.2.6 Cell Viability Assay 
 
After the MDA-MB-231 cells reached 60% confluency, the cell culture media was 
aspirated away, triple washed and replaced by RPMI 1640 without phenol red. PX-loaded 
protein micelle solution was added to the cell culture at working PX concentrations of 35, 
105, and 350 nM. Following an incubation time of 3-15 hours, cell culture was 
trypsinized and resuspended in RPMI 1640 without phenol red, mixed with equal volume 
of 0.4% trypan blue solution that only stained dead cells. The mixture solution was 
injected into a hemacytometer (Reichert Bright-Line) and incubated at room temperature 
for 90 seconds. The total number of cells and number of stained cells were counted under 
an optical microscope within 1 minute after incubation. The cell viability was recorded as 




3.3 Results and Discussions 
3.3.1 Oleosin Design, Self-Assembly and Secondary Structure  
 
Previously, we have created two variants from oleosin-30G(-) that serve as controls. The 
positive control RGDS-30G(-) contains an integrin-binding motif RGDS to the N-
terminus and has been observed to increase uptake by breast cancer cells by a factor of 
4.6. The negative control RADS-30G(-) contains an nonactive peptide sequence RADS 
(Arg-Ala-Asp-Ser) at the same location and does not increase protein uptake significantly 
over 15 hours (Figure 3.1).   
 
In this current study, initially three further variants were created from oleosin 
30G(-) to incorporate PHSRN and Tat-peptide and study their effects on enhancing 
cellular uptake. PHSRN-30G(-) was designed to have PHSRN (Pro-His-Ser-Arg-Asn) 
attached to the end of the N-terminus hydrophilic arm. To study the colocaliztion effect 
of PHSRN and RGDS ligands, PHSRN-30G(-)-RGDS was engineered to have PHSRN 
and RGDS on the same oleosin molecule, with PHSRN at the N-terminus and RGDS 
(Arg-Gly-Asp-Ser) at the C-terminus. RGDS-30G(-)-Tat incorporated RGDS and Tat 
(Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Gln) at the ends of the N- and C- 




To monitor the purity of the recombinant oleosin products and confirm that the 
mutated oleosin has the exact peptide sequence as designed, SDS-PAGE and MALDI-
TOF (Matrix-Assisted Laser Desorption/Ionization – Time of Flight) were performed on 
each sample after purification. Both tests confirmed that the recombinant oleosin 
products are highly purified and monodisperse in molecular weight (Figure 3.2). CMC 
(critical micelle concentration) was determined using a pyrene assay (Table 3.1). 
Dynamic light scattering (DLS) was used to verify that the protein self-assembles into 
micellar structures above CMC (Figure 3.3).  The secondary structures were analyzed by 
CDSSTR and shown in Figure 3.4. 
 
 

















RADS-30G(-) 15376 15372 3.6 21.23 0.196 
RGDS-30G(-) 15362 5358 3.6 20.96 0.189 
PHSRN-30G(-) 15538 15531 3.4 19.97 0.192 
PHSRN-30G(-)-RGDS 15954 15950 3.6 20.22 0.190 
Tat-30G(-) 16644 16638 3.3 22.01 0.197 










Figure 3.2. Protein characterization and MALDI-TOF spectrum. Protein purity was 
measured after IMAC purification to be >95% with SDS-PAGE. Protein molecular 
weight was confirmed by MALDI-TOF and closely match expected weights of protein 




Figure 3.3. Dynamic Light Scattering of all recombinant oleosin variants. Measurement 
taken at 10 μM and DLS spectrum suggests spherical micellar formation. Hydrodynamic 




Figure 3.4. Secondary structure of protein variants. CDSSTR analysis shows 30%-40% 
of the secondary structure for all oleosin variants are unordered, while the Tat-30G(-) has 
a slightly higher sheet structure.  
 
3.3.2 Oleosin Micelle Uptake by Breast Cancer Cells Measured 
with Flow Cytometry 
 
The cellular uptake study was carried out on MDA-MB-231 cell line, a human breast 
cancer cell line that has been shown to upregulate the RGDS binding domain αvβ3 63,85,86. 
After the breast cancer cell culture reached 60-70% confluency, DyLight-488 labeled 
protein micelles were introduced to the cell culture media at 10 μM. The cell culture was 
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then put back to 37 °C incubation to mimic physiological conditions. Time points were 
taken at 3, 6, 9 and 15 hours before unbound material was washed away. Cells were then 
immediately resuspended and analyzed with flow cytometry, or immediately labeled to 
visualized the cell membrane and fixed for confocal microscopy.  
 
First, the flow cytometry quantification methods was validated by comparing to 
the previously published the cellular uptake of the positive and negative controls by the 
MDA-MB-231 cell line, where cellular uptake was quantified via cell counting.90 The 
flow cytometry results on cellular uptakes of previously published variants resemble the 
trends observed through cell counting, indicating that an additional RGDS motif 
increased the cellular uptake by 2.5x in 15 hours. A representative flow cytometry 
spectrum is shown in Figure 3.5 and the uptake of each variant shown in Figure 3.6. 
 
The additional Tat-peptide on the C-terminus showed significantly enhanced 
cellular uptake at all time points. Compared to the RGDS alone, the Tat-peptide increases 
cellular uptake by factors of 1.32, 1.43, 1.86, and 1.93 at 3 hours, 6 hours, 9 hours, and 15 
hours respectively. The Tat-peptide acted as a effective cell penetration peptide that 
enhanced the performance of the bioactive ligand RGDS. 
 
On the other hand, the additional PHSRN on the N-terminus did not lead to 
significant different cellular uptake when compared to the negative control RADS-30G(-). 
PHSRN-30G(-)-RGDS variant possessed co-localized PHSRN and RGDS motifs and 
performed similarly to the RGDS-30G(-), where only the RGDS motif and present. These 
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results suggest that PHSRN alone does not stimulate cellular uptake. To further 
investigate the effect of co-localized RGDS and PHSRN, PHSRN-30G(-) and RGDS-
30G(-) were blended at various ratios for the cellular uptake study, which is discussed at 
the following section.  
 
 
Figure 3.5. Flow cytometry histogram showing fluorescence of MDA-MB-231 cells 
under treatments for 15 hours. Grey histogram corresponds to PBS as blank, black 
histogram corresponds to the negative control 10 μM RADS-30G(-), and green histogram 

















3.3.3 Effect of RGDS vs. PHSRN Ligand Concentration on 
Cellular Uptake 
 
To investigate the effect of the ligand ratio between RGDS and PHSRN on cellular 
uptake, RGDS-30G(-) and PHSRN-30G(-) were blended at ratios of 7:3, 5:5, and 3:7, 
adjusted to a final concentration of 10 μM and tested for cellular uptake by MDA-MA-
231 cells at 37 °C for 15 hours. The flow cytometry results are shown in Figure 3.7, 
where the uptake of RGDS-30G(-), PHSRN-30G(-) and PHSRN-30G(-)-RGDS were 
included as comparison.  
 
While the peptide ligand concentration was kept at 10 μM, an interesting 
observation was the comparison of cell uptake levels of 5:5 RGDS-30G(-):PHSRN-30G(-
), PHSRN-30G(-) and RGDS-30G(-). The 5:5 blend construct is able to reach the same 
uptake level as the positive control RGDS-30G(-), and suggests that the PHSRN act 
synergistically with RGDS on integrin mediated cell uptake. The blend of 7:3 RGDS-
30G(-):PHSRN-30G(-) resulted in significantly higher cellular uptake than other blend 
ratios. The cellular uptake of this particular blend at the end of 15 hours led to a 1.5x 
increase than the positive control RGDS-30G(-), and was statistically parallel to the 
PHSRN-30G(-)-RGDS, where the ligand concentration is doubled.  The behavior of cell 
uptake based on ligand ratios may be explained by the spatial distance between ligands. 
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Altering the ratios between RGDS and PHSRN effective changes the mean spatial 
distance between the two ligands, and in this work the 7:3 blend may resemble the natural 
distance between PHSRN and RGD in fibronectin. The comparison between the 7:3 and 
3:7 blends suggest that RGDS is essential in achieving integrin mediated cell uptake, 
which agrees with previous work.    
 
 
Figure 3.7. Cellular uptake of blended RGDS-30G(-) and PHSRN-30G(-) variants at a 
final concentration of 10 μM, by MDA-MB-231 cells at 37°C for 15 hours. * indicates 






3.3.4 Paclitaxel Encapsulation 
 
Paclitaxel encapsulation were carried out to investigate the cargo ability of oleosin 
micelles. To test the encapsulation efficiency of oleosin micelles, paclitaxel was 
fluorescently labeled, mixed with oleosin micellar solution by brief sonication, then let 
recover at room temperature for at least 10 minutes. A fluorescent level vs. paclitaxel 
concentration was established with a Fluoromax-4 spectrophotometer (Horiba Jobin 
Yvon) and used to obtain paclitaxel concentration after encapsulation. The encapsulation 
efficiency of oleosin micelles were found to be around 3.2%, and samples were adjusted 







Figure 3.8. Paclitaxel emission intensity (excitation 496 nm, emission 524) vs. 
concentration. Data was linear fitted and the calibration equation is y= 206.7x – 4686, 
R^2 = 0.99.  
 
3.3.5 Integrin Mediated Cell Killing 
 
Oleosin micelles with a paclitaxel cargo were dosed on MDA-MB-231 cells at paclitaxel 
concentrations of 35 nM, 105 nM, and 350 nM, and cell viability were collected at 3 
hour, 6 hour, 9 hour, and 15 hour time points, shown in Figure 3.9. Drug delivery was 
visualized by encapsulating paclitaxel with fluorescently labeled oleosin and imaged with 
confocal microscopy, shown in Figure 3.10. The z-stack series images indicate effective 




The cell killing rate from the viability study follows the trend observed with flow 
cytometry. Variants that have high cellular uptake levels observed in flow cytometry also 
have high cell killing rates. PBS and RADS-30(-) without paclitaxel solutions were tested 
as negative controls, and indicated that oleosin itself does not exhibit cell killing abilities 
in the absence of paclitaxel.   
 
Effect of functionalized oleosin micelles as drug carriers can be observed by 
comparing cell viability of breast cancer cell treated with paclitaxel encapsulated in 
oleosin micelles to the cells treated with paclitaxel solution at the same concentration. At 
15 hours, the positive control RGDS-30G(-) improves the cell killing rate by 1.3x with 35 
nM and 105 nM paclitaxel, and by 1.6x with 350 nM paclitaxel. Variant PHSRN-30G(-) 
where only PHSRN is present does not significantly facilitate cell killing, where the 
synergy between PHSRN and RGDS as demonstrated by variant PHSRN-30G(-)-RGDS 
increased cell killing by 1.18x with 350 nM paclitaxel at 15 hours.  
 
To better understand the effect of Tat-peptide on increasing cellular penetration 
and achieving cell killing, a new variant Tat-30G(-) with the Tat peptide attached to the 
N-terminus was created for the cell viability study (Figure 3.1). The characterizations of 
this new variant is similar to other variants presented in this study, and are listed in Table 
3.1 and Figure 3.2, Figure 3.3, and Figure 3.4.  The Tat-peptide alone does not 
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significantly improve cell killing at 35 nM paclitaxel, but increases cell killing by around 
1.2x at 105 nM and 350 nM paclitaxel.  
 
The RGDS-30G(-)-Tat peptide achieved a 88% cell killing with 350 nM 
paclitaxel in 15 hours, an 1.95x increase than the same concentration of paclitaxel 
solution not encapsulated by protein micelles, and an 1.2x increase than RGDS-30G(-) 
where only RGDS is present, and 1.6x increase than the Tat peptide alone. These results 
indicated that oleosin micelles can successfully deliver a hydrophobic cargo into breast 
cancer cells and achieve cell killing, and Tat peptide is an effective CCP that assisted cell 




Figure 3.9. Percentage of live cells at the end of cell viability study, quantified by the 
trypan blue assay. White bar, grey bar, and black bar represent final paclitaxel 




Figure 3.10. In vitro confocal microscopy images of DyLight 488 labeled RGDS-30G(-)-
Tat on MDA-MB-231 cells, incubated for 15 h under 37 °C, scale bar represents 50 μm. 
Each panel is (a) 488 nm channel showing labeled oleosin micelles, (b) 633 nm channel 
cell membrane labeled with Alexa Fluor 633, and (c) merged channels where labeled 




Finally, the cell viability was repeated for blends of 1:1 Tat-30G(-) : RGDS-30G(-
) and 1:1 RADS-30G(-) : RGDS-30G(-)-Tat to investigate the effects of Tat on cell 
penetration, shown in Figure 3.11. The two blends of oleosin variants have statistically 
similar cell killings, and do not improve cell killing than the Tat-30G(-) variant where 
only Tat is present. In the scope of this study, there is no evidence that suggests that the 
Tat peptide and RGDS motif interfere with each other. The RGDS-30G(-)-Tat remains as 
the variant with the highest cell killing potential.  
 
 
Figure 3.11. Viability of MDA-MB-231 cells treated with (a) 35 nM paclitaxel (b) 105 
nM paclitaxel and (c) 350 nM paclitaxel encapsulated with oleosin 30G(-) variants, under 






In this study, we explored the effects of PHSRN and the Tat peptides on cellular uptake, 
and proved oleosin micelles as a practical tool towards targeted drug delivery. We have 
shown that PHSRN act synergistically with RGDS when both present on the same 
oleosin micelle, and this synergy effect can be further tuned by altering PHSRN and 
RGDS ligand ratios. In addition, we have created a variant of oleosin, RGDS-30G(-)-Tat, 
that incorporated both integrin bioactivity as well as a cell penetrating peptide, which can 
significantly improve cellular uptake. We have also proved that the oleosin micelles are 
capable of carrying a paclitaxel cargo that fits the therapeutic dosing concentration, can 
be effectively internalized by breast cancer cells, and achieve cell killing. These 
constructs of oleosin variants broadened our understanding on ligand behavior and 
interactions, and established oleosin micelle as a stable and versatile drug carrier. There 
exists a huge body of information about cellular metabolic and signaling pathways yet to 
be made applicable in practice, and oleosin presents an exciting new solution that can 
transfer theoretical knowledge to applications.  
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Chapter 4. Oleosin Drug 










The targeted delivery of chemotherapeutic agents to specific cell lines is becoming an 
attrative solution to localize drugs on desired disease cells and reduce systematic side 
effect. Members of the erbB family receptor tyrosine kinases are shown to overexpress in 
a variety of human cancer cells and are important targets for the design of a smart drug 
carrier. Previously, AFA and BPT peptide ligands were identified to bind to and inhibit 
erbB receptors, which raised the possibility of targeting erbB recpetors as a mean of drug 
delivery. However, the limitations of current synthesized materials make it difficult to 
generate a carrier that can be functionalized with these identified peptide ligands with a 
uniform quality. Here we present recombinant oleosin as an alternative drug delivery 
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material and created an series of recombinant oleosin variants functionalzied with AFA 
and BPT ligands. The new variants self-assemble into spherical micellar structures, can 
encapsulate a therapeutic dose of paclitaxel, and achieve 50% cell killing of lung cancer 
cells in vitro in 4 hours, and 90% cell killing in 16 hours. The variants presented here 






In this work, we took the previously established knowledge on oleosin functionalization 
and explore outside the regime of RGDS bioactivity and breast cancer cell lines. 
Members of the erbB family receptor tyrosine kinases (erbB1, erbB2, erbB3, and erbB4) 
are overexpressed in a variety of human cancers, and are important targets for the design 
of drugs and drug carriers.100–103 Approaches in targeting erbB receptors include 
monoclonal antibodies, ligand-linked immunotoxins, antisense, and tyrosine kinase 
inhibitors.100,101,103,104   
 
An interesting approach developed by Murali et al. to disable erbB receptor 
activity was to target protein-protein interaction surfaces.100,105 Protein-protein 
interactions plays an important role in mechanisms of cell growth and differentiation, and 
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emerges as a promising approach towards rational targeted drug delivery design. Murali 
et al. has demonstrated that two peptide ligand sequences, AFA (YCFPDEEGACY) and 
BPT (PCPINCTHSCVDLDDKGCPAEQRASPLTSI) exhibit outstanding binding 
affinity to all three receptors of erbB1, erB2, and erbB3.  
 
We have previously engineered oleosin to self-assemble into spherical micelles, 
incorporate one or multiple bioactivities, and carry a payload of anti-cancer drug 
paclitaxel. These oleosin variants can be readily engineered for specific drug delivery 
applications. Here we present a new series of oleosin variants, incorporated with AFA 
and BPT peptides, and investigate their potential of being paclitaxel carriers targeted with 
non-small cell lung cancer cells. 
 
This work is in collaboration with Dr. Ramachandran Murali’s lab, who 
discovered the peptide sequences and established parameters such as integrin binding 









4.2 Materials and Methods  
 
4.2.1    Protein Design and Expression  
 
Oleosin Gene Construction and Expression: Modified genes were ordered from 
Integrated DNA Technologies and were inserted into the expression vector pBamUK and 
later transformed into the BL21 (DE3) strain of E. coli for expression. DNA sequencing 
was performed before protein expression by the E. coli strain BL21 DE3 (Stratagene) 
controlled by the lac promotor on the pBamUK. Cultures are grown at 37°C in Luria 
Broth (LB) with 50 μg/ml kanamycin until OD600 reaches 0.6. Isopropyl β-D-
thiogalactoside (IPTG) was added to the culture to a final concentration of 1.0 mM to 
induce the expression of oleosin. Cells were collected by spinning down the culture at 
15,000g for 15min and were kept frozen at -20°C until purification. All oleosin variants 
presented in this study adds a 6-histidine tag to the C-terminus of oleosin molecule which 
facilitates purification through immobilized metal affinity chromatography (IMAC). All 
variants of proteins in this study express solubly. Yields for all variants in this study were 
within the range of 40-100 mg of purified protein per liter of culture. All oleosin variants 





Protein Purification: All oleosin strands in this study have 6-Histidine tag to the C-
terminus and were purified with Ni-NTA columns (Pierce). All protein strands in this 
study are soluble and can be purified with the protocol suggested by Vargo et al.31 In 
brief, frozen protein pellet was re-suspended in B-PER Bacterial Protein Extraction 
Reagent (Fisher). After spinning down at 15,000g for 15min, the supernatant was left to 
bind with the Ni-NTA resin for at least 1 hour. Then the column was repeatedly washed 
and protein sample was eluted out.  
 
4.2.2    Protein Characterization  
 
SDS-PAGE: To determine the purity of protein samples, purified oleosin samples were 
loaded on NuPAGE Novex 4-12% Bis-Tris mini gels (Invitrogen) in 2-(N-morpholino)-
ethanesulfonic acid (MES) buffer. SimplyBlue SafeStain (Invitrogen) was used to stain 
the gel following electrophoresis. The gel was imaged with a Kodak Gel Logic 100 
imaging system. 
 
Mass Spectroscopy: To prepare matrix solution, sinapinic acid was added to 50:50 (v/v) 
ACN: [0.1 vol.% TFA in water] to a final concentration of 10mg/ml. 0.5 μL of matrix 
solution was added to Bruker AnchorChip, immediately followed by 0.5 μL of oleosin 
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solution. Solutions were mixed on the AnchorChip using a pipet tip and air-dried. 
Samples were analyzed with matrix-assisted laser desorption ionization (MALDI) mass 
spectroscopy (Bruker, PennChemistry Mass Spectrometry Facility).   
 
Circular Dichroism (CD): An AVIV 410 spectrometer (AVIV Biomedical, Inc.) was 
used to collect UV CD spectra at 25°C in a 1 mm quartz cell. The protein sample 
concentration was 10 μM in 50 mM phosphate and 140 mM NaF. The CD data was 
analyzed with the CDSSTR algorithm using Dichroweb. 
 
Dynamic Light Scattering (DLS): 700 μL of protein sample was added to a small-
volume cuvette cleaned with compressed air. DLS was performed with a Malvern 
Zetasizer Nano ZS (Westborough, MA). 
 
4.2.3    Mammalian Cell Culture  
 
The human lung cancer cell line NCI-H1975 (ATCC CRL-5908) was acquired from 
ATCC. NCI-H1975 cells were cultured in RPMI 1640 (Life Technologies 22400) 
supplemented with 10% heat-inactivated fetal bovine serum (Sigma Aldrich F2442) and 
100 units/ml penicillin and 100 μg/ml streptomycin (Life Technologies 15140) on tissue-




4.2.4    Paclitaxel Encapsulation  
 
Paclitaxel (ThermoFisher P3456) was resuspended in 200 proof ethanol and carefully 
injected into oleosin micellar solution at concentration of 20 μM. The mixture was then 
briefly sonicated for 20 seconds and let sit for 10 minutes in room temperature. The 
mixture was then dialyzed against PBS. Protein concentration was measured by 
Nanodrop and adjusted to 10 μM. Each sample was verified to be in micellar solution 
form with Dynamic Light Scattering (DLS) before dosed onto cells. The encapsulation 
efficiency of paclitaxel by oleosin was measured with a labeled version of paclitaxel 
(ThermoFisher P22310). A calibration of paclitaxel fluorescence signal vs. concentration 
was established with a Fluoromax-4 spectrophotometer (Horiba Jobin Yvon), and the 
procedure described here resulted in a 3.21±1.2% encapsulating efficiency of paclitaxel. 
 
4.2.5    Cell Viability Studies  
 
Trypan Blue: Cell culture was trypsinized and resuspended in RPMI 1640 without 
phenol red (Life Technologies 11835) and mixed with equal volume of 0.4% trypan blue 
solution (ThermoFisher 15250061) with only stained dead cells. The mixture solution 
was injected into a hemacytometer (Reichert Bright-Line) and incubated at room 
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temperature for 90 seconds. The total number of cells and number of stained cells were 
counted under an optical microscope within 1 minute after incubation. The cell viability 
was recorded as: 
 
 
MTT: 12 mM MTT stock solution was prepared by adding 1mL of sterile PBS to 5 mg of 
MTT (ThermoFisher V13154). Solubilization solution was prepared by adding 10 mL of 
0.01 M HCL to 1 g of SDS (ThermoFisher V13154) immediately before use.  
10 μL of the 12 mM MTT stock solution was added to each well and the cell culture was 
incubated at 37°C for 4 hours. 100 μL of the solubilization solution was added to each 
well and mixed by gently pipetting. The cell culture was then incubated at a 37°C 
humidified incubator for 12 hours. After the solubilization step, the sample was mixed by 
pipetting and absorbance was recorded at 570 nm. The cell viability in this study was 
determined by: 
 
Blank samples were prepared by adding 100 μL of RPMI 1640 without phenol red to 




4.3 Results and Discussions 
 
4.3.1 Oleosin Design, Self-Assembly and Secondary Structure  
 
In this current study, seven further variants were created from oleosin 30G(-) and 
30G family to incorporate AFA and BPT and study their effects on enhancing cellular 
uptake. AFA-30G-63 was engineered to have the AFA ligand at the N-terminus. AFA-
30G-43 was mutated to truncate the C-terminus hydrophilic arm to 43 amino acids, such 
that by theory the AFA will be more exposed when self-assembled into a spherical 
micelle. AFA-30G(-) was a variant where both of the hydrophilic arms were negatively 
charged. Three versions incorporating BPT ligand were constructed in the same fashion. 
CD4-G is a peptide ligand known to not interact with erbB receptors and therefore CD4-
G-30G-43 was constructed to have CD4-G at the N-terminus and serve as the negative 
control in this study. All variant constructs are illustrated in Figure 4.1. 
 
To monitor the purity of the recombinant oleosin products and confirm that the 
mutated oleosin has the exact peptide sequence as designed, SDS-PAGE and MALDI-
TOF (Matrix-Assisted Laser Desorption/Ionization – Time of Flight) were performed on 
each sample after purification. Both tests confirmed that the recombinant oleosin 
products are highly purified and monodisperse in molecular weight (Figure 4.2). 
Dynamic light scattering (DLS) was used to verify that the protein self-assembles into 
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micellar structures at 10 μM (Figure 4.3), with the detailed characteristics listed in Table 





























AFA-30G-63 16194 16192 22.46 0.186 
AFA-30G-43 14254 14244 20.96 0.168 
AFA-30G(-) 16225 16220 21.60 0.173 
BPT-30G-63 16715 16708 23.33 0.183 
BPT-30G-43 14775 14767 20.98 0.168 






Figure 4.2. Protein characterization and MALDI-TOF spectrum. Protein purity was 
measured after IMAC purification to be >95% with SDS-PAGE. Protein molecular 
weight was confirmed by MALDI-TOF and closely match expected weights of protein 





Figure 4.3. Dynamic Light Scattering of all recombinant oleosin variants. Measurement 
taken at 10 μM and DLS spectrum suggests spherical micellar formation. Hydrodynamic 





Figure 4.4. Secondary structure of protein variants. CDSSTR analysis shows 60%-80% 
of the secondary structure for all oleosin variants are unordered, with the exceptions of 
AFA-30G(-) and BPT-30G(-), where both hydrophlic arms are negatively charged and 














4.3.2 Integrin Mediated Cell Killing 
 
In previous research, the trypan blue assay was used as the quantification method of cell 
viability. Although easy to implement and reflects true incubation times, the trypan blue 
method has a limited precision due to the cell resuspension and manual cell counting. A 
second assessment tool, the MTT assay, was carried out in this work in parallel to the 
trypan blue assay.  
 
The MTT assay requires a 4-hour incubation time after the time point, and 
therefore does not provide information for cell viability within 4 hours. A dilemma with 
the MTT assay is that MTT assay results are indications of average metabolic active level 
of the cell culture within the incubation time, which tend to overestimate actual cell 
viability and does not provide information on an exact time point. To best overcome this, 
cell viabilities in this study were measured at every 4 hours for 16 hours, which gives 
each data point from the MTT assay two benchmarks from the trypan blue assay. 
Regardless of the technical issues, the trends of cell viabilities measured from both assays 
still provide valuable information on the ability of functionalized oleosin to deliver drug 




First, paclitaxel not encapsulated by oleosin and paclitaxel encapsulated by the 
non-bioactive variant CD4-G-30G-43 were tested as negative controls, with the cell 
viability results shown in Figure 4.5 and Figure 4.6.  CD4-G-30G-43 does not 
significantly improve cell killing, and in fact shown to slightly decrease cell killing at 
high paclitaxel concentrations. This indicates that CD4-G ligand binds poorly to 
receptors, and the encapsulation of paclitaxel made it less accessible to cross the cell 




Figure 4.5. Percentage of live cells at the end of cell viability study. White bar, grey bar, 










Figure 4.6. Cell viability study results on CD4-G-30-43 as the drug carrier. White bar, 
grey bar, and black bar represent final paclitaxel concentrations at 35 nM, 105 nM and 
350 nM, respectively.  
 
 
On the other hand, oleosin variants functionalized with AFA and BPT ligands act 
as effective drug carriers and can increase cell killing significantly in as short as 4 hours. 
The AFA family of oleosin demonstrates an even higher cell killing in general than the 
BPT family. In high paclitaxel concentration and 16 hours, The AFA functionalized 
carriers achieved cell killing rate at over 75%, and the BPT functionalized carriers 
achieved celling rate at around 70%. Out of all the new variants presented here, AFA-
30G-43 is the most effective drug carrier. In 350 nM paclitaxel conditions measured by 
trypan blue, the AFA-30G-43 led to a 2.3x, 2.0x, 1.9x, and 1.85x increased cellular 
uptake than paclitaxel in free form in 4, 8, 12, and 16 hours respectively. Both trypan 
blue and MTT assays indicate that AFA-30G-43 with 350 nM paclitaxel results in cell 




Within each family of oleosin, the ligand-30G-43 construct (AFA-30G-43 and 
BPT-30G-43) is the best drug carrier at delivery drug and result in cell killing. This 
observation may be explained by the truncation of the C-terminus hydrophilic arm. When 
self-assembled into spherical micelles, the ligand-30G-43 constructs will offer the ligand 
better exposure since the non-functionalized C-terminus hydrophilic arm has less number 




Figure 4.7. Cell viability study results on AFA variants as the drug carrier. White bar, 
grey bar, and black bar represent final paclitaxel concentrations at 35 nM, 105 nM and 





Figure 4.8. Cell viability study results on BPT variants as the drug carrier. White bar, 
grey bar, and black bar represent final paclitaxel concentrations at 35 nM, 105 nM and 








Finally, we investigated the effect of blending in the previously studies cell-
penetrating peptide Tat into the best performing variant AFA-30G-43. 1:1 blend of AFA-
30G-43 : Tat-30G(-) was repeated for the cell viability essay with 350 nM paclitaxel, 
quantified by trypan blue assay. Tat-30G(-) and 1:1 blend of AFA-30G-43 : CD4-G-43 
were carried out as a controls. The cell viability results are shown in Figure 4.9.  
 
In this case, the blend of AFA and Tat peptide does not indicate any advantage in 
cell killing. This could be explained by comparing the cell viability where Tat-30G(-) and 
AFA-30G-43 are used as drug carriers. The cell killing rate from using AFA-30G-43 was 
3x – 1.2x higher than Tat-30G(-), from 4 hours to 16 hours. This indicates that AFA-
30G-43 has a stronger binding affinity to receptors on NCI-H1975 cells than the Tat-
30G(-) variant. The longer arm on the C-terminus of the Tat-30G(-) molecule could also 
contribute to the lower cell killing.   
 
Drug delivery was visualized by encapsulating paclitaxel with fluorescently 
labeled oleosin and imaged with confocal microscopy. The z-stack series images of AFA-
30G-43 on NCI-H1975 at 15 hours are shown in Figure 4.10, indicating effective cell 
internalization of oleosin micelles, and some degree of localization within the cell. Wide 
field confocal images of cells treated with paclitaxel loaded CD4-G-30G-43, AFA family 
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variants, and BPT family variants are shown in Figure 4.11, Figure 4.12, and Figure 




Figure 4.9. Viability of NCI-H1975 cells treated with 350 nM paclitaxel encapsulated 





Figure 4.10. In vitro confocal microscopy images of DyLight 488 labeled AFA-30G-43 
on NCI-H1975 cells, incubated for 15 h under 37 °C, scale bar represents 50 μm. Each 
panel is (left) 488 nm channel showing labeled oleosin micelles, (middle) 633 nm 
channel cell membrane labeled with Alexa Fluor 633, and (right) merged channels where 
labeled oleosin in shown in green and cell membrane is shown in red. Each panel is 2.5 





Figure 4.11. In vitro confocal microscopy images of DyLight 488 labeled CD4-G-30G-
43 on NCI-H1975 cells, incubated for 15 h under 37 °C, scale bar represents 100 μm. 
Each panel is (left) 488 nm channel showing labeled oleosin micelles, (middle) 633 nm 
channel cell membrane labeled with Alexa Fluor 633, and (right) merged channels where 










Figure 4.12. In vitro confocal microscopy images of DyLight 488 labeled (a) AFA-30G-
63 and (b) AFA-30G(-) on NCI-H1975 cells, incubated for 15 h under 37 °C, scale bar 
represents 100 μm. Each panel is (left) 488 nm channel showing labeled oleosin micelles, 
(middle) 633 nm channel cell membrane labeled with Alexa Fluor 633, and (right) 







Figure 4.13. In vitro confocal microscopy images of DyLight 488 labeled (a) BPT-30G-
43, (b) BPT-30G-63, and (c) BPT-30G(-) on NCI-H1975 cells, incubated for 15 h under 
37 °C, scale bar represents 100 μm. Each panel is (left) 488 nm channel showing labeled 
oleosin micelles, (middle) 633 nm channel cell membrane labeled with Alexa Fluor 633, 
and (right) merged channels where labeled oleosin in shown in green and cell membrane 









This work demonstrates the engineering of the naturally occurring surfactant protein 
oleosin towards drug carriers that targets a range of erbB receptors, and results in a 
significantly increased lung cancer cell killing. We have shown that the oleosin 30G and 
30G(-) family can be mutated to carry peptide ligands as large as 30 amino acids on one 
hydrophilic arm, and retain their spherical micellar self-assembly structure. One 
particular variant, the AFA-30G-43 achieved the fastest cell killing observed in this 
thesis. The method of using recombinant oleosin as the platform of building drug carriers 
demonstrated here is powerful as it can make research in simulation phase readily 
available for in vitro studies. We envision oleosin micelles to be a promising toolbox that 
can be easily converted for targeted drug delivery, as well as a range of other therapeutic 












5.1 Specific Aims 
 
 
The research presented within this thesis shows that we are able to successfully create 
biomaterials from the surfactant protein oleosin, and use it towards targeted drug 
delivery. The specific aims of this work were as follows: 
 
1. Create a recombinant oleosin that is bioactive and answers to an environmental 
cue in physiological conditions 
2. Encapsulate an anti-cancer drug in self-assembled oleosin nanostructure, and 
achieve specific cell killing 




5.2 Specific Findings 
 
 
5.2.1 Create a recombinant oleosin that is bioactive and 
answers to an environmental cue in physiological conditions 
 
Chapter 2 focuses on creating an oleosin variant that is both integrin-targeted and 
answers to a environmental cue. To achieve this, a variant Throm-RGDS-30G(-) is 
created where the bioactive RGDS ligand is shielded by 20 amino acids, and only 
becomes exposed when in the presence of thrombin. The resulting molecule expresses 
well, and self-assembles into a spherical micelle shape in aqueous environments. The 
cellular uptake by a breast cancer cell line (MDA-MB-231) was quantified with confocal 
imaging, and the results indicates that the bioactive motif RGDS is only fully exposed by 
the specific protease thrombin. This work completes Aim I of the thesis, and became the 





5.2.2 Encapsulate an anti-cancer drug in self-assembled oleosin 
nanostructure, and achieve specific cell killing 
 
Moving on from Aim I, Chapter 3 of this work set out to investigate the potential of 
engineering oleosin to become a practical drug carrier. Thus, this work explored a range 
of questions, from enhancing cellular uptake of the existing RGDS motif, to 
encapsulating an anti-cancer drug in a protein micelle. Three new variants incorporating 
PHSRN and Tat peptide was initially mutated from the oleosin 30G(-) family, and test for 
cellular uptake with an improved quantification tool flow cytometry. It was discovered 
that both PHSRN and Tat peptide enhances the cellular uptake of RGDS-30G(-), and 
different oleosin variants can be blended at different ratios to further fine-tune the 
synergy effect.  We have also proved that the oleosin micelles are capable of carrying a 
paclitaxel cargo that fits the therapeutic dosing concentration, can be effectively 
internalized by breast cancer cells, and achieve cell killing. One particular variant, 
RGDS-30G(-)-Tat, achieves 88% breast cancer killing in 15 hours when carrying a 350 
nM paclitaxel cargo. This work provides practical insight in turning oleosin into a 





5.2.3 Expand the oleosin library to target multiple cell lines 
 
In Chapter 4, we collaborated with Dr. Ramachandran Murali and investigated the ability 
of oleosin as drug carriers that targets non-small cell lung cancer cell lines. Six new 
variants were constructed to incorporate AFA and BPT ligands, which binds to erbB1, 
erbB2, and erbB3 receptors. Oleosin variants were shown to be stable micellar forms 
after adding a peptide ligand as large as 30 amino acids, and encapsulating paclitaxel in a 
range of 35 nM to 350 nM. The non-functionalized arm was trimmed down such that the 
added ligand is more exposed. The resulting AFA-30G-43 variants presents a 50% cell 
killing in as short as 4 hours, and kills 90% of cells in 12 hours with a 350 nM paclitaxel 
cargo. Chapter 4 shows examples of oleosin variants that can target multiple cell lines, 









5.3 Future Directions 
 
The work presented in this thesis arise from the oleosin’s unique triblock construct, and 
ability of be precisely engineered via molecular biology. We have demonstrated many 
mutations of oleosin that are engineered to be bioactive, and investigate their physical 
stability and capability of carrying a cargo. However, the potential of generating 
bioactive mutants from oleosin has very little limit. Numerous mutants can be generated 
from oleosin to improve on the work presented here, to deepen our understanding of 
using oleosin as drug carriers, or to explore other applications. Here, I will discuss ideas 
for expansion and extension of the aims finished in this dissertation.   
 
5.3.1 Immunogenicity Screening 
 
Immunogenicity is the ability of substances (such as antigen and epitope) to trigger an 
immune response in human or animal bodies. The immunogenic response includes both 
cellular (T cell) and humoral (antibody) immune responses and is an important but 
sometimes overlooked aspect of drug discovery. Anti-drug antibodies (ADA) elicited by 
therapeutics may decrease the therapeutic effect of the drug, and in more serious cases 
lead to autoimmune thrombocytopenia and pure red cell aplasia.106,107 Most protein 
therapeutics induce an unwanted immune response, and the rational next step of the 
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research presented in this thesis is to screen for the lowest immunogenetic oleosin 
variant.107–109  
 
While the immune response is a complicated cascade, T cell – dependent 
responses appear to play a critical role in the development of antibody responses.110 
Predictive tools build upon the empirical results from clinical immune response results, 
and use amino acid pairwise contact potentials to calculate peptide binding to MHC class 
I and II alleles.111–114   
 
A preliminary algorithm by Calis et al. predicts immunogenicity of peptides using 
the NetNHC-3.2 algothrim, the best performing predictor according to a large benchmark 
study.115,116 This algorithm is a part of the Immune Epitope Database (IEDB) and can be 
freely accessed at http://tools.iedb.org/immunogenicity/. The predicted Class I 
immunogenicity scores of oleosin variants presented in this thesis are listed in Table 5.1. 
 
A non-immunogenetic peptide in the algorithm by Calis et al. has a score of 0, 
and a higher score indicated a higher possibility of the peptide eliciting an immune 
response. According to this predicting algorithm, oleosin with a large hydrophobic core 
and uncharged hydrophilic arms are less likely to trigger an immune response, which can 
be a hypothesis for future research. This algorithm, like most available predicting 
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algorithms, are only validated for short peptides (around 9 amino acids long). Definitive 
information on the immunogenicity of oleosin variants can be obtained by doing ELISA 
antibody assays.  
 
From an oleosin variants with established functionalities, an array of similar 
oleosin variants can be engineered with alternations in the non-functional regions and 
screened for the lowest immunogenic variant. The power of generating a library of fully 
functional variants for immunogenicity screening is unique to recombinant protein, which 
makes recombinant protein a well-rounded material for drug delivery purposes.  
 
Table 5.1. Immunogenicity Score of Oleosin Variants 
Oleosin- Immunogenicity Score* 





















5.3.2 Physical Properties and Stability  
 
We have established reliable methods that measures basic physical properties of oleosin 
such as hydrodynamic size, critical micelle concentration, and secondary structures. The 
limitation of current measurements is the resolution of observing oleosin molecules and 
micelles finer than the nanoscale. The typical size of oleosin micelles is around 20 nm, 
which makes it difficult to visualize in cryo-TEM, the most advanced imaging tool we 
have tried on oleosin so far. AFM has been shown to be a powerful imaging tool that 
provide information on much smaller length scales, and recent advancements in AFM 
makes it possible to image a soft ensemble body such as oleosin micelles in solutions. 
Creating a simulation model of oleosin molecules is also promising in predicting oleosin 
behavior in the designing phase. Oleosin molecules are typically in the 100-200 amino 
acid range, which makes them a realistic goal for calculation. These future directions will 
offer us new information on oleosin, thus helping with understanding and predicting 
oleosin behaviors.  
   
In the scope of this thesis, we have observed that the self-assembled micelle 
structure of oleosin is stable for at least one month in 4°C, and for at least 24 hours at 
37°C in mammalian cell culture conditions. The assembly structure is also shown to 
recover itself after a brief perturbation such as sonication up to 30 seconds. These 
observations made oleosin a practical tool for drug delivery, and a rational next step is to 
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investigate oleosin stability in a more complex condition that resembles blood circulation. 
A good in vitro simulation of blood flow can be achieved through microfluidics, where 
the shape of channels, flow rates, and channel surfaces can all be modified to simulate a 
range of physiological conditions. Microfluidic devices generated in Dr. Daeyeon Lee’s 
lab and Dr. Scott Diamond’s lab have seen promising results in simulating blood flow 
and offer direct visualization, and can be great collaboration projects in the future.  
 
Cytotoxicity of oleosin has been measured on cancer cell lines, and preliminary 
results suggest that the negative control of RADS-30G(-) does not exhibit toxicity when 
compared to PBS. The next steps in this direction is to measure cytotoxicity of a small 
library of oleosin on healthy cells such as epithelial cells. In Chapter 4, we have 
demonstrated MTT to be fast and reliable way to measuring cell proliferation. Healthy 
epithelial cells can be seeded in 96 well plates, dosed with oleosin micellar solutions, and 






5.3.3 Functionalized Oleosin in Other Self-Assembled 
Structures 
 
Previously, our lab has seen promising results where oleosin variants can assemble into 
shapes such as worm-like micelles, bilayer sheets, and vesicles.30 We have observed that 
insoluble mutants of oleosin are more promising in assembling to more complex 
structures due to their large hydrophobic core, and that highly asymmetrical variants tend 
to form into worm-like micelles. These complex constructs have great potential in 
applications of drug delivery and tissue engineering. Vesicles can carry both hydrophobic 
and hydrophilic cargos, and worm-like micelles and bilayer sheets have the more surface 
contact area per molecule with cells than any other nanoscale structures. However, 
creating those complex structures faced several major limitations. First, those structures 
were made through emulsion templating instead of self-assembly, which makes the final 
products unpredictable in sizes. The organic solvents used during emulsion templating 
also limit the further applications in physiological conditions. Second, the large 
hydrophobic core (87 amino acids) causes poor expression in bacteria, and the surfactant 
being insoluble makes it difficult to purify and store.  
 
Future work on making complex structures from oleosin would need to focus on 
making the oleosin soluble. We have carried out some preliminary work in starting with a 
insoluble protein in the 87 family and switching out some amino acids that possess high 
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alpha helix structure, and amino acids that leads to hydrogen bonds, aiming to make the 
hydrophobic core more flexible and possibly increasing solubility. Even though no 
mutants have been found to tune the 87 family to complete soluble protein yet, this 
approach is still the most promising in obtaining a variant that self-assemble into a 
vesicle. Some additional approaches include changing the hydrophilic arm to charged 
amino acids. Switching all amino acids on the hydrophilic arm to be negatively or 
positively charged proteins is most promising in making the structure flexible through 
repulsion of the arms, but could lead to perturbed self-assembly structure.  
 
Another interesting area to explore is to add multiple protease cleavable domains to the 
hydrophilic arms of oleosin, and thus creating a molecule that’s susceptible to a cascade 
of enzyme reactions. We have demonstrated that thrombin can be successfully 
incorporated into the oleosin 30G(-) family, and there’s a high possibility for other short 
cleavable sites to be inserted into the hydrophilic arms. The applications of this direction 
are sustained release of cargo and change of structure post-assembly.  
 





In this thesis, we have established solid knowledge on using oleosin as drug carriers that 
targets breast cancer cell lines and lung cancer cell lines, and there remains much need in 
the drug delivery field that oleosin can readily tackle. To expand upon the work presented 
here, one can incorporate other drugs, target other cell lines, and transfer to the diagnostic 
field.  
 
In Chapter 3 and Chapter 4, we have demonstrated that oleosin micelles can 
encapsulate a hydrophobic drug paclitaxel, which is a common anti-cancer drug. Other 
hydrophobic drugs include doxorubicin hydrochloride (DOX), and groups of steroids. 
Most of the hydrophobic drug delivery is still in microencapsulation stage, and requires a 
volatile organic solvent to dissolve the encapsulation matrix and sometimes the drug as 
well.117 Oleosin micelle is a promising approach that will bypass the organic solvent and 
make the drug more readily accessible.  
 
In Chapter 2 and Chapter 3 of this work, there has been a focus on using RGDS as 
the bioactive motif. One limitation of using RGDS towards targeted drug delivery is the 
non-specificity of RGDS. RGDS binds to more than half of the over 20 integrins studied 
in the human body, and using RGDS as the vector for targeted drug delivery typically 
requires assistance such as localized injection. In Chapter 4 we have proved that the 
oleosin 30G and 30G(-) family are capable of incorporating peptide ligands up to the size 
of 30 amino acids on one hydrophilic arm, which opens up opportunities for the 
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incorporation of a number of other ligands with higher specificity, as well as sensitivity 
towards some pathologically relevant enzymes.  
 
This work has demonstrated the potential in engineering oleosin towards targeted 
drug delivery applications, and the future directions mentioned here contain rational 
routes to deepen our understanding of oleosin and make it even closer to actual 
application, as well as ways where our knowledge of oleosin can be used for other 
applications. The field of bioactive ligand and pathological pathways is continuously 
evolving at a rate faster than conventional chemically synthesized materials can 
accommodate, and oleosin emerges as a powerful and versatile platform that transforms 
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Appendix: DNA and Protein 
Sequences 
 
Variant DNA Sequence AA Sequence 
30G GGATCCACCACAACCTACGACCGCCACC
ATGTCACCACCACCCAACCCCAATACCGC
CATGATCAACACACCGGTGACAGACTCA
CCCACCCACAGCGCCAGCAACAAGGCCC
CTCAACCGGCAAGCTCGCTCTCGGTGCGA
CTCCGCTGTTTGGTGTTATAGGTTTCAGC
CCTGTTATTGTTCCAGCGATGGGTATAGC
GATTGGGCTTGCGGGTGTTACCGGGTTTC
AGAGGGATTATGTGAAGGGGAAGTTGCA
GGATGTGGGGGAGTATACGGGCCAGAAG
ACGAAGGACTTGGGCCAGAAGATACAGC
ATACGGCCCATGAAATGGGTGACCAGGG
CCAGGGTCAGGGTCAGGGTGGTGGGAAA
GAAGGGCGAAAAGAAGGGGGGAAACTC
GAGCACCACCACCACCACCAC 
GSTTTYDRHH
VTTTQPQYRH
DQHTGDRLTH
PQRQQQGPST
GKLALGATPL
FGVIGFSPVIV
PAMGIAIGLA
GVTGFQRDY
VKGKLQDVG
EYTGQKTKDL
GQKIQHTAHE
MGDQGQGQG
QGGGKEGRK
EGGKLEHHH
HHH 
RADS-30G(-) GGATCCCGCGCGGATAGCGAAGCCACAA
CAACCAACGACCAGCACAAAGTCACCAC
CACCCAACCCCAAGATCAGCATGATCAA
CACACCGGTGACCAGCTCACCCACCCAC
AGGACCAGCAACAAGGCCCCTCAACCGG
CGAACTCGCTCTCGGTGCGACTCCGCTGT
TTGGTGTTATAGGTTTCAGCCCTGTTATT
GTTCCAGCGATGGGTATAGCGATTGGGCT
TGCGGGTGTTACCGGGTTTCAGTGGCAGG
ATAACGTGAACGGGGAATTGCAGGATGT
GGGGGAGCAGACGGGCCAGAACACGAA
CGACTTGGGCCAGCAGATACAGCATACG
GCCCATGAAATGGGTGACCAGGGCCAGG
GTCAGGGTCAGGGTGGTGGGAACGAAGG
GCAGAACGAAGGGGGGAACCACCACCAC
CACCACCACGATGAC 
GSRADSEATT
TNDQHKVTTT
QPQDQHDQH
TGDQLTHPQD
QQQGPSTGEL
ALGATPLFGV
IGFSPVIVPAM
GIAIGLAGVT
GFQWQDNVN
GELQDVGEQT
GQNTNDLGQ
QIQHTAHEMG
DQGQGQGQG
GGNEGQNEG
GNHHHHHHD
D 
131 
 
RGDS-30G(-) GGATCCCGCGGCGATAGCGAAGCCACAA
CAACCAACGACCAGCACAAAGTCACCAC
CACCCAACCCCAAGATCAGCATGATCAA
CACACCGGTGACCAGCTCACCCACCCAC
AGGACCAGCAACAAGGCCCCTCAACCGG
CGAACTCGCTCTCGGTGCGACTCCGCTGT
TTGGTGTTATAGGTTTCAGCCCTGTTATT
GTTCCAGCGATGGGTATAGCGATTGGGCT
TGCGGGTGTTACCGGGTTTCAGTGGCAGG
ATAACGTGAACGGGGAATTGCAGGATGT
GGGGGAGCAGACGGGCCAGAACACGAA
CGACTTGGGCCAGCAGATACAGCATACG
GCCCATGAAATGGGTGACCAGGGCCAGG
GTCAGGGTCAGGGTGGTGGGAACGAAGG
GCAGAACGAAGGGGGGAACCACCACCAC
CACCACCACGATGAC 
GSRGDSEATT
TNDQHKVTTT
QPQDQHDQH
TGDQLTHPQD
QQQGPSTGEL
ALGATPLFGV
IGFSPVIVPAM
GIAIGLAGVT
GFQWQDNVN
GELQDVGEQT
GQNTNDLGQ
QIQHTAHEMG
DQGQGQGQG
GGNEGQNEG
GNHHHHHHD
D 
Oleosin-
Throm-
RADS-30G(-) 
 
GGATCCGAAGCCACCACAACCAACGACC
AGCACCATGTCACCACCACCCAACCCCA
AGATCAGAAACTGGTGCCGCGTGGTAGC
CGCGCCGATAGCGATCAAAAAACCGGTG
ACCAGCTCACCCACCCACAGGACCAGCA
ACAAGGCCCCTCAACCGGCGAACTCGCT
CTCGGTGCGACTCCGCTGTTTGGTGTTAT
AGGTTTCAGCCCTGTTATTGTTCCAGCGA
TGGGTATAGCGATTGGGCTTGCGGGTGTT
ACCGGGTTTCAGTGGCAGGATAACGTGA
ACGGGGAATTGCAGGATGTGGGGGAGCA
GACGGGCCAGAACACGAACCTGGTTCCG
CGCGGCTCTGACTTGGGCCAGCAGATAC
AGCATACGGCCCATGAAATGGGTGACCA
GGGCCAGGGTCAGGGTCAGGGTGGTGGG
AACGAAGGGCAGAACGAAGGGGGGAAC
CACCACCACCACCACCACGATGACTGA  
 
GSEATTTNDQ
HHVTTTQPQD
QKLVPRGSRA
DSDQKTGDQ
LTHPQDQQQG
PSTGELALGA
TPLFGVIGFSP
VIVPAMGIAIG
LAGVTGFQW
QDNVNGELQ
DVGEQTGQN
TNLVPRGSDL
GQQIQHTAHE
MGDQGQGQG
QGGGNEGQN
EGGNHHHHH
HDD 
 
132 
 
Oleosin-
Throm-
RGDS-30G(-) 
 
GGATCCGAAGCCACCACAACCAACGACC
AGCACCATGTCACCACCACCCAACCCCA
AGATCAGAAACTGGTGCCGCGTGGTAGC
CGCGGCGATAGCGATCAAAAAACCGGTG
ACCAGCTCACCCACCCACAGGACCAGCA
ACAAGGCCCCTCAACCGGCGAACTCGCT
CTCGGTGCGACTCCGCTGTTTGGTGTTAT
AGGTTTCAGCCCTGTTATTGTTCCAGCGA
TGGGTATAGCGATTGGGCTTGCGGGTGTT
ACCGGGTTTCAGTGGCAGGATAACGTGA
ACGGGGAATTGCAGGATGTGGGGGAGCA
GACGGGCCAGAACACGAACCTGGTTCCG
CGCGGCTCTGACTTGGGCCAGCAGATAC
AGCATACGGCCCATGAAATGGGTGACCA
GGGCCAGGGTCAGGGTCAGGGTGGTGGG
AACGAAGGGCAGAACGAAGGGGGGAAC
CACCACCACCACCACCACGATGACTGA  
 
GSEATTTNDQ
HHVTTTQPQD
QKLVPRGSRG
DSDQKTGDQ
LTHPQDQQQG
PSTGELALGA
TPLFGVIGFSP
VIVPAMGIAIG
LAGVTGFQW
QDNVNGELQ
DVGEQTGQN
TNLVPRGSDL
GQQIQHTAHE
MGDQGQGQG
QGGGNEGQN
EGGNHHHHH
HDD 
 
RGDS-30G(-)-
Tat 
GGATCCCGCGGCGATAGCGAAGCCACAA
CAACCAACGACCAGCACAAAGTCACCAC
CACCCAACCCCAAGATCAGCATGATCAA
CACACCGGTGACCAGCTCACCCACCCAC
AGGACCAGCAACAAGGCCCCTCAACCGG
CGAACTCGCTCTCGGTGCGACTCCGCTGT
TTGGTGTTATAGGTTTCAGCCCTGTTATT
GTTCCAGCGATGGGTATAGCGATTGGGCT
TGCGGGTGTTACCGGGTTTCAGTGGCAGG
ATAACGTGAACGGGGAATTGCAGGATGT
GGGGGAGCAGACGGGCCAGAACACGAA
CGACTTGGGCCAGCAGATACAGCATACG
GCCCATGAAATGGGTGACCAGGGCCAGG
GTCAGGGTCAGGGTGGTGGGAACGAAGG
GCAGAACGAAGGGGGGAACGGCCGCAA
AAAACGCCGCCAGCGCCGCCGCCCGCAG
TGCCACCATCACCATCACCATGATGAC 
GSRGDSEATT
TNDQHKVTTT
QPQDQHDQH
TGDQLTHPQD
QQQGPSTGEL
ALGATPLFGV
IGFSPVIVPAM
GIAIGLAGVT
GFQWQDNVN
GELQDVGEQT
GQNTNDLGQ
QIQHTAHEMG
DQGQGQGQG
GGNEGQNEG
GNGRKKRRQ
RRRPQCHHHH
HHDD 
PHSRN-30G(-
) 
GGATCCCCGCATAGCCGCAACGAAGCCA
CAACAACCAACGACCAGCACAAAGTCAC
CACCACCCAACCCCAAGATCAGCATGAT
CAACACACCGGTGACCAGCTCACCCACC
CACAGGACCAGCAACAAGGCCCCTCAAC
CGGCGAACTCGCTCTCGGTGCGACTCCGC
TGTTTGGTGTTATAGGTTTCAGCCCTGTT
GSPHSRNEAT
TTNDQHKVTT
TQPQDQHDQ
HTGDQLTHPQ
DQQQGPSTGE
LALGATPLFG
VIGFSPVIVPA
133 
 
ATTGTTCCAGCGATGGGTATAGCGATTGG
GCTTGCGGGTGTTACCGGGTTTCAGTGGC
AGGATAACGTGAACGGGGAATTGCAGGA
TGTGGGGGAGCAGACGGGCCAGAACACG
AACGACTTGGGCCAGCAGATACAGCATA
CGGCCCATGAAATGGGTGACCAGGGCCA
GGGTCAGGGTCAGGGTGGTGGGAACGAA
GGGCAGAACGAAGGGGGGAACCACCATC
ACCATCACCATGATGAC 
MGIAIGLAGV
TGFQWQDNV
NGELQDVGE
QTGQNTNDL
GQQIQHTAHE
MGDQGQGQG
QGGGNEGQN
EGGNHHHHH
HDD 
PHSRN-30G(-
)-RGDS 
GGATCCCCGCATAGCCGCAACGAAGCCA
CAACAACCAACGACCAGCACAAAGTCAC
CACCACCCAACCCCAAGATCAGCATGAT
CAACACACCGGTGACCAGCTCACCCACC
CACAGGACCAGCAACAAGGCCCCTCAAC
CGGCGAACTCGCTCTCGGTGCGACTCCGC
TGTTTGGTGTTATAGGTTTCAGCCCTGTT
ATTGTTCCAGCGATGGGTATAGCGATTGG
GCTTGCGGGTGTTACCGGGTTTCAGTGGC
AGGATAACGTGAACGGGGAATTGCAGGA
TGTGGGGGAGCAGACGGGCCAGAACACG
AACGACTTGGGCCAGCAGATACAGCATA
CGGCCCATGAAATGGGTGACCAGGGCCA
GGGTCAGGGTCAGGGTGGTGGGAACGAA
GGGCAGAACGAAGGGGGGAACCGCGGC
GATAGCCACCATCACCATCACCATGATG
AC 
GSPHSRNEAT
TTNDQHKVTT
TQPQDQHDQ
HTGDQLTHPQ
DQQQGPSTGE
LALGATPLFG
VIGFSPVIVPA
MGIAIGLAGV
TGFQWQDNV
NGELQDVGE
QTGQNTNDL
GQQIQHTAHE
MGDQGQGQG
QGGGNEGQN
EGGNRGDSH
HHHHHDD 
134 
 
Tat-30G(-) GGATCCGGCCGCAAAAAACGCCGCCAGC
GCCGCCGCCCGCAGTGCGAAGCCACAAC
AACCAACGACCAGCACAAAGTCACCACC
ACCCAACCCCAAGATCAGCATGATCAAC
ACACCGGTGACCAGCTCACCCACCCACA
GGACCAGCAACAAGGCCCCTCAACCGGC
GAACTCGCTCTCGGTGCGACTCCGCTGTT
TGGTGTTATAGGTTTCAGCCCTGTTATTG
TTCCAGCGATGGGTATAGCGATTGGGCTT
GCGGGTGTTACCGGGTTTCAGTGGCAGG
ATAACGTGAACGGGGAATTGCAGGATGT
GGGGGAGCAGACGGGCCAGAACACGAA
CGACTTGGGCCAGCAGATACAGCATACG
GCCCATGAAATGGGTGACCAGGGCCAGG
GTCAGGGTCAGGGTGGTGGGAACGAAGG
GCAGAACGAAGGGGGGAACCACCACCAC
CACCACCACGATGAC 
GSGRKKRRQR
RRPQCEATTT
NDQHKVTTT
QPQDQHDQH
TGDQLTHPQD
QQQGPSTGEL
ALGATPLFGV
IGFSPVIVPAM
GIAIGLAGVT
GFQWQDNVN
GELQDVGEQT
GQNTNDLGQ
QIQHTAHEMG
DQGQGQGQG
GGNEGQNEG
GNHHHHHHD
D 
AFA-30G-63 GGATCCATGTATTGCTTTCCGGATGAAGA
AGGCGCGTGCTATACCACAACCTACGAC
CGCCACCATGTCACCACCACCCAACCCCA
ATACCGCCATGATCAACACACCGGTGAC
AGACTCACCCACCCACAGCGCCAGCAAC
AAGGCCCCTCAACCGGCAAGCTCGCTCTC
GGTGCGACTCCGCTGTTTGGTGTTATAGG
TTTCAGCCCTGTTATTGTTCCAGCGATGG
GTATAGCGATTGGGCTTGCGGGTGTTACC
GGGTTTCAGAGGGATTATGTGAAGGGGA
AGTTGCAGGATGTGGGGGAGTATACGGG
CCAGAAGACGAAGGACTTGGGCCAGAAG
ATACAGCATACGGCCCATGAAATGGGTG
ACCAGGGCCAGGGTCAGGGTCAGGGTGG
TGGGAAAGAAGGGCGAAAAGAAGGGGG
GAAACATCACCATCACCATCAC 
GSMYCFPDEE
GACYTTTYDR
HHVTTTQPQY
RHDQHTGDR
LTHPQRQQQG
PSTGKLALGA
TPLFGVIGFSP
VIVPAMGIAIG
LAGVTGFQRD
YVKGKLQDV
GEYTGQKTK
DLGQKIQHTA
HEMGDQGQG
QGQGGGKEG
RKEGGKHHH
HHH 
AFA-30G-43 GGATCCATGTATTGCTTTCCGGATGAAGA
AGGCGCGTGCTAT 
ACCACAACCTACGACCGCCACCATGTCA
CCACCACCCAACCCCAATACCGCCATGAT
CAACACACCGGTGACAGACTCACCCACC
CACAGCGCCAGCAACAAGGCCCCTCAAC
CGGCAAGCTCGCTCTCGGTGCGACTCCGC
TGTTTGGTGTTATAGGTTTCAGCCCTGTT
ATTGTTCCAGCGATGGGTATAGCGATTGG
GSMYCFPDEE
GACYTTTYDR
HHVTTTQPQY
RHDQHTGDR
LTHPQRQQQG
PSTGKLALGA
TPLFGVIGFSP
VIVPAMGIAIG
LAGVTGFQRD
135 
 
GCTTGCGGGTGTTACCGGGTTTCAGAGGG
ATTATGTGAAGGGGAAGTTGCAGGATGT
GGGGGAGTATACGGGCCAGAAGACGAAG
GACTTGGGCCAGAAGATACAGCATACGG
CCCATGAAATGGGTCATCACCATCACCAT
CAC 
YVKGKLQDV
GEYTGQKTK
DLGQKIQHTA
HEMGHHHHH
H 
BPT-30G-63 GGATCCATGCCGTGCCCGATTAACTGCAC
CCATAGCTGCGTGGATCTGGATGATAAA
GGCACCACAACCTACGACCGCCACCATG
TCACCACCACCCAACCCCAATACCGCCAT
GATCAACACACCGGTGACAGACTCACCC
ACCCACAGCGCCAGCAACAAGGCCCCTC
AACCGGCAAGCTCGCTCTCGGTGCGACTC
CGCTGTTTGGTGTTATAGGTTTCAGCCCT
GTTATTGTTCCAGCGATGGGTATAGCGAT
TGGGCTTGCGGGTGTTACCGGGTTTCAGA
GGGATTATGTGAAGGGGAAGTTGCAGGA
TGTGGGGGAGTATACGGGCCAGAAGACG
AAGGACTTGGGCCAGAAGATACAGCATA
CGGCCCATGAAATGGGTGACCAGGGCCA
GGGTCAGGGTCAGGGTGGTGGGAAAGAA
GGGCGAAAAGAAGGGGGGAAACATCAC
CATCACCATCAC 
GSMPCPINCT
HSCVDLDDK
GTTTYDRHHV
TTTQPQYRHD
QHTGDRLTHP
QRQQQGPSTG
KLALGATPLF
GVIGFSPVIVP
AMGIAIGLAG
VTGFQRDYV
KGKLQDVGE
YTGQKTKDL
GQKIQHTAHE
MGDQGQGQG
QGGGKEGRK
EGGKHHHHH
H 
BPT-30G-43 GGATCCATGCCGTGCCCGATTAACTGCAC
CCATAGCTGCGTGGATCTGGATGATAAA
GGCACCACAACCTACGACCGCCACCATG
TCACCACCACCCAACCCCAATACCGCCAT
GATCAACACACCGGTGACAGACTCACCC
ACCCACAGCGCCAGCAACAAGGCCCCTC
AACCGGCAAGCTCGCTCTCGGTGCGACTC
CGCTGTTTGGTGTTATAGGTTTCAGCCCT
GTTATTGTTCCAGCGATGGGTATAGCGAT
TGGGCTTGCGGGTGTTACCGGGTTTCAGA
GGGATTATGTGAAGGGGAAGTTGCAGGA
TGTGGGGGAGTATACGGGCCAGAAGACG
AAGGACTTGGGCCAGAAGATACAGCATA
CGGCCCATGAAATGGGTCATCACCATCA
CCATCAC 
GSMPCPINCT
HSCVDLDDK
GTTTYDRHHV
TTTQPQYRHD
QHTGDRLTHP
QRQQQGPSTG
KLALGATPLF
GVIGFSPVIVP
AMGIAIGLAG
VTGFQRDYV
KGKLQDVGE
YTGQKTKDL
GQKIQHTAHE
MGHHHHHH 
136 
 
AFA-30G(-) GGATCCTATTGCTTTCCGGATGAAGAAGG
CGCGTGCTATGAAGCCACAACAACCAAC
GACCAGCACAAAGTCACCACCACCCAAC
CCCAAGATCAGCATGATCAACACACCGG
TGACCAGCTCACCCACCCACAGGACCAG
CAACAAGGCCCCTCAACCGGCGAACTCG
CTCTCGGTGCGACTCCGCTGTTTGGTGTT
ATAGGTTTCAGCCCTGTTATTGTTCCAGC
GATGGGTATAGCGATTGGGCTTGCGGGT
GTTACCGGGTTTCAGTGGCAGGATAACGT
GAACGGGGAATTGCAGGATGTGGGGGAG
CAGACGGGCCAGAACACGAACGACTTGG
GCCAGCAGATACAGCATACGGCCCATGA
AATGGGTGACCAGGGCCAGGGTCAGGGT
CAGGGTGGTGGGAACGAAGGGCAGAACG
AAGGGGGGAACCATCACCATCACCATCA
CGATGAC 
GSYCFPDEEG
ACYEATTTND
QHKVTTTQPQ
DQHDQHTGD
QLTHPQDQQQ
GPSTGELALG
ATPLFGVIGFS
PVIVPAMGIAI
GLAGVTGFQ
WQDNVNGEL
QDVGEQTGQ
NTNDLGQQIQ
HTAHEMGDQ
GQGQGQGGG
NEGQNEGGN
HHHHHHDD 
BPT-30G(-) GGATCCCCGTGCCCGATTAACTGCACCCA
TAGCTGCGTGGATCTGGATGATAAAGGC
GAAGCCACAACAACCAACGACCAGCACA
AAGTCACCACCACCCAACCCCAAGATCA
GCATGATCAACACACCGGTGACCAGCTC
ACCCACCCACAGGACCAGCAACAAGGCC
CCTCAACCGGCGAACTCGCTCTCGGTGCG
ACTCCGCTGTTTGGTGTTATAGGTTTCAG
CCCTGTTATTGTTCCAGCGATGGGTATAG
CGATTGGGCTTGCGGGTGTTACCGGGTTT
CAGTGGCAGGATAACGTGAACGGGGAAT
TGCAGGATGTGGGGGAGCAGACGGGCCA
GAACACGAACGACTTGGGCCAGCAGATA
CAGCATACGGCCCATGAAATGGGTGACC
AGGGCCAGGGTCAGGGTCAGGGTGGTGG
GAACGAAGGGCAGAACGAAGGGGGGAA
CCATCACCATCACCATCACGATGAC 
GSPCPINCTHS
CVDLDDKGE
ATTTNDQHK
VTTTQPQDQH
DQHTGDQLT
HPQDQQQGPS
TGELALGATP
LFGVIGFSPVI
VPAMGIAIGL
AGVTGFQWQ
DNVNGELQD
VGEQTGQNT
NDLGQQIQHT
AHEMGDQGQ
GQGQGGGNE
GQNEGGNHH
HHHHDD 
137 
 
CD4-G-30G-43 GGATCCTTTTGCTATATTGGCGAAGTGGAAGATCA
GTGCTAT 
ACCACAACCTACGACCGCCACCATGTCACCACCA
CCCAACCCCAATACCGCCATGATCAACACACCGG
TGACAGACTCACCCACCCACAGCGCCAGCAACAA
GGCCCCTCAACCGGCAAGCTCGCTCTCGGTGCGA
CTCCGCTGTTTGGTGTTATAGGTTTCAGCCCTGTT
ATTGTTCCAGCGATGGGTATAGCGATTGGGCTTGC
GGGTGTTACCGGGTTTCAGAGGGATTATGTGAAG
GGGAAGTTGCAGGATGTGGGGGAGTATACGGGCC
AGAAGACGAAGGACTTGGGCCAGAAGATACAGC
ATACGGCCCATGAAATGGGTCATCACCATCACCA
TCAC  
 
GSFCYIGEVEDQ
CYTTTYDRHHVT
TTQPQYRHDQHT
GDRLTHPQRQQQ
GPSTGKLALGAT
PLFGVIGFSPVIVP
AMGIAIGLAGVT
GFQRDYVKGKL
QDVGEYTGQKT
KDLGQKIQHTAH
EMGHHHHHH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
